Author: Ryan Allway

FinCanna’s Investment, Cultivation Technologies, Secures Distribution Across California and Commenced Sales of its Coachella™ Premium Cannabis Concentrates and Vape Cartridges

Written by Ryan Allway on Jun 04, 2018

California a key market for FinCanna’s royalty investment model as it is estimated to be valued over US$24 billion by 2025

VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (OTCQB:FNNZF), a royalty company for the U.S. licensed medical cannabis industry, provides the following update on Cultivation Technologies, Inc. (“CTI”), its first investment in California.  CTI announced today that its Coachella™ Premium brand of cannabis concentrates and vape cartridges is expanding its retail presence, securing distribution in ten dispensaries across California.

Coachella™ Premium, which procures craft cannabis from artisan, licensed cultivators to produce some of the highest quality concentrates in California is now being sold at ten California locations, including premier dispensaries, Connected Cannabis (multiple locations), Lighthouse (Coachella), 420 Central (Santa Ana), and From the Earth (Santa Ana).

“We are very pleased with the growth and expansion of the Coachella™ Premium brand throughout California and are impressed with the quality of dispensaries that are selling the products. Concentrate and Vape sales generate high margin revenue for FinCanna and its shareholders,” said Andriyko Herchak, President and CEO of FinCanna Capital. “These leading dispensaries, choose only the highest quality, premium brands in a rapidly growing market which we are very excited to a part of.  We see an incredible future for the company while it continues to expand its brand presence across California, the largest market in North America.”

The Coachella™ Premium line of products features all the major concentrate types including diamonds, sauce, shatter, batter, and sugar, with an ongoing list of strains. Coachella™ Premium vape cartridges feature organic fruit terpenes and all-natural cannabis-derived terpenes for extraordinary flavors. Initial market feedback gathered during the product development phase indicates that Coachella™ Premium brand vape cartridges offer a unique proposition within the vaporizer sector – one of the fastest growing verticals in the cannabis market.

All Coachella™ Premium products, unlike a majority of concentrates in the marketplace, undergo full panel testing and a scoring process, where only select batches are approved for distribution under the Coachella™ Premium brand label.

Coachella Manufacturing is one of the first companies to operate a legal solvent extraction facility for cannabis in California. The company produces THC concentrates through BHO extraction to create custom formulations at its state-of-the-art, licensed lab which includes the latest in cold storage, extraction and distillation technologies. The company is working to maximize commercialization of its products from the facility, which can process an estimated 6,000 pounds of biomass per month translating to approximately 3.7 million grams of raw cannabis oil per year.

About Cultivation Technologies
Cultivation Technologies, Inc. provides infrastructure, technology, and branding to the licensed medical cannabis industry. The first major project for the company is in Coachella, California, which will span 6-acres featuring cultivation centers, extraction and manufacturing facilities, a testing lab, a distribution hub, and a centralized processing center. For more information, visit www.CultivationTech.com.

About FinCanna Capital Corp.
FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues.  FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California.  For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, President & CEO

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about FinCanna’s ability to source suitable projects, the development and construction of the CTI’s facility at Coachella, and the size and success of operations at the Extraction Facility and FinCanna’s ability to generate revenues therefrom.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

 

Primary Logo

 

Source: GlobeNewswire (June 4, 2018 – 3:05 AM EDT)

The post FinCanna’s Investment, Cultivation Technologies, Secures Distribution Across California and Commenced Sales of its Coachella™ Premium Cannabis Concentrates and Vape Cartridges appeared first on CannabisFN.

WeedMD Reports First Quarter Financial Results

Written by Ryan Allway on May 31, 2018

WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, has reported its financial and operating results for the first quarter ending March 31, 2018.

WeedMD is pleased to report revenues of $1.14 million for the first quarter of 2018. Revenues consisted of the sale of dried medical cannabis, live cannabis plants and cannabis oils, to both patients and through wholesale B2B channels. The Company also maintained a strong cash balance of $48 million as of the end of the quarter.

“With sales up 33% quarter over quarter, we are incredibly proud of what our team has achieved and we look forward to continued strong revenue growth throughout the remainder of 2018,” said Keith Merker, CFO of WeedMD. “We are nearing the second-site Health Canada Cultivation License for our large-scale, state-of-the-art, greenhouse expansion and are pleased to confirm that we have continued to successfully ramp up our operations, with our headcount increasing by an impressive 60% since the start of the year. Our recent merger announcement with Hiku and its coast-to-coast brand and retail footprint will enable the Company to be vertically integrated and control the full supply-chain, from seed to sale.” (See Hiku Brands Company Ltd. (CSE:HIKU) and WeedMD merger press release here).

For the three month period ended March 31st 2018 2017
($) ($)
Revenue 1,142,341 –
Net Comprehensive Loss 1,446,497 1,192,474
Adjusted Operating Loss¹ 1,279,439 1,070,369
Cash Used from Operations 652,783 429,985
Loss per Share (Basic and Fully Diluted) 0.01 0.03
As at March 31, 2018 December 31, 2017
  ($) ($)
Cash and Cash Equivalents 48,460,059 24,692,678
Total Assets 73,676,391 39,605,187
Total Liabilities 12,521,352 14,472,639
Working Capital 50,991,564 25,713,807

¹Adjusted Operating Loss is not a recognized measurement under IFRS and this data may not be comparable to data presented by other companies. Management believes Adjusted Operating Loss to be an important measure of the Company’s day-to-day operations, by excluding non-cash gains and losses and/or non-recurring items.

STRATHROY UPDATE

WeedMD continues to be on budget with the retrofit of Phase I of its 610,000 sq. ft. state-of-the-art greenhouse in Strathroy, ON. The Company anticipates securing a license for this facility by the end of the second quarter of 2018.

  • Situated on 98-acres of property with 610,000 sq. ft. or 14 acres of existing greenhouse structure in addition to ancillary buildings.
  • Phase I retrofit represents 220,000 sq. ft. of tempered glass greenhouse which is less than two years old.
  • With features such as full climate-control, supplemental lighting and black-out curtains, WeedMD has combined the best of indoor and greenhouse cultivation to create a true “hybrid” greenhouse
  • Equipped with an on-site unlimited supply of natural clean water.
  • Modern fertigation system runs on full-recirculation loop which provides an accurate, innovative computerized method of monitoring plant nutrients and water. This will ensure that water is recycled and reused and does not leach into the surrounding area and that WeedMD meets its environmental responsibilities.
  • Boiler exhaust is scrubbed of CO2, cleaned and then utilized for production providing significant cost savings and ensuring optimal plant growth.

OPERATIONAL AND CORPORATE HIGHLIGHTS

  • Closed the previously announced, oversubscribed $34.5 million bought deal equity financing.
  • Commenced the sale of cannabis oil products under the company’s EntourageTM and AxisTM brands.
  • Submitted an application to obtain a Health Canada Dealer’s Licence under the Controlled Drugs and Substances Act.
  • Appointed Kevin McGovern, chairman of McGovern Capital and founder of the beverage company SoBe, the fastest growing beverage company ever in the United States, as a board director.
  • Appointed Dr. Jonas Vanderzwan, a physician with more than 15 years of primary care experience, as Medical Director and Chair of the Clinical Advisory Board.
  • Completed strategic investments in Blockstrain Technology Corp. (TSX-V:DNAX), which has developed a comprehensive cannabis genetics archiving platform, and Snipp Interactive Inc. (TSX-V:SPN), a global loyalty and promotions company focused on disruptive engagement platforms for consumers.
  • Ramped up the retrofit of a large-scale, fully-funded greenhouse expansion comprising 610,000 sq. ft., with 220,000 sq. ft. coming online in 2018. The expansion remains on-track and within budget, with first harvests expected in Summer 2018.
  • Entered into a partnership with the Technion-Israel Institute of Technology, joining the world-renown Cannabis Database Project, and collaborating on research of 25 of WeedMD’s strains
  • Purchased the land and building of the Aylmer facility for $1,500,000.

SUBSEQUENT EVENTS

  • On April 19, 2018, entered into a definitive agreement to merge with Hiku Brands, bringing together two highly-complementary businesses and creating a unique and market-differentiating vertically integrated company with an industry-leading portfolio of brands, growing retail footprint, and significant cannabis production capabilities. For more information on the transaction, please see Hiku’s investor presentation.

The Company’s financial statements and related management’s discussion and analysis for the period are available under the Company’s profile on SEDAR at www.sedar.com. All amounts are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards unless otherwise noted.

About WeedMD Inc.:

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis and oils under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. The Company is focused on providing medical cannabis to the seniors’ markets in Canada through its proprietary seniors care program. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

The post WeedMD Reports First Quarter Financial Results appeared first on CannabisFN.

Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries

Written by Ryan Allway on

KELOWNA, BC / ACCESSWIRE / May 31, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ”Company” or ”Lexaria”), a drug delivery platform innovator, announces that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property (”IP”) related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (”NSAIDs”), phosphodiesterase (”PDE5”) inhibitors and other active pharmaceutical ingredients.

This proposed structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. It is expected that Lexaria’s patented DehydraTECHTM technology will be utilized by both subsidiaries.

Lexaria recently announced lab test results related to delivery of nicotine through the gastrointestinal tract and superior nicotine absorption in animal blood plasma with two particularly significant findings:

  1. Speed of onset – as much nicotine delivered to the bloodstream in 15 minutes with the Lexaria technology vs. nearly 3 hours in the control group.
  2. Bioavailability – approximately 560% more nicotine into brain tissue than the control formulation.

These discoveries have led to increased and ongoing dialogue with leading nicotine industry participants regarding the possible utilization of Lexaria’s technology. Lexaria believes that these organizational changes could enable significant increases in shareholder value while meeting the diverse needs of providing services to different industry sectors.

Separately, the Company announces that pursuant to existing stock option plans, it has granted stock options to directors, officers, employees and consultants that enable the option holders to purchase up to 1,725,000 common shares of the Company at a price of US$1.53 for a period of five years, vesting immediately.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for applications of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, NSAIDs, PDE5 inhibitors, nicotine and other molecules. www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. There is no assurance that ongoing dialogue with leading nicotine industry participants will lead to any benefit to the Company. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

The post Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries appeared first on CannabisFN.

Pivot Signs Option Agreement to Acquire Licensing Rights to Patented TriVair™ Nasal and Pulmonary Drug Delivery System For Its “RTIC” Ready-To-Infuse-Cannabis Powder

Written by Ryan Allway on

VANCOUVER, May 31, 2018 /PRNewswire/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to announce that the Company has signed an Option Agreement with IP Med Inc., based in Oceanside, New York, to acquire an exclusive worldwide license for Trivair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery of Pivot’s Ready-To-Infuse-Cannabis (“RTIC”) cannabinoid products. The Option expires in 6-months during which time Pivot will determine compatibility with Pivot’s RTIC powder formulations. Upon successful completion of the evaluation Pivot will have the Option to enter into a Definitive Licensing Agreement with IP Med for the TriVair™ device.

Winner of the Frost and Sullivan 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, the intuitive and easy-to-use TriVair™ patented devices are discreet and disposable, deliver pre-loaded precise unit doses and eliminate the risk of microbial contamination. Clinical studies using the TriVair™ Delivery System have demonstrated that the powder compound is widely distributed in all areas of the nasal cavity (with no area of powder accumulation), is effective in retaining medication in the nasal cavity without pharyngeal penetration and showed a high degree of patient acceptability.

The TriVair™ Nasal device uses the body’s natural breath to propel a medication deep into the nasal cavity to targeted sites, bypassing the Blood Brain Barrier, providing the potential to better treat central nervous system diseases such as migraines, epilepsy, insomnia, and post-operative pain, the latter of which is often remedied by opioids. The TriVair™ Pulmonary device enables specific dosing to the pulmonary airways, thereby targeting the lungs. Such targeting can be highly relevant in the treatment of respiratory diseases and in the prevention and treatment of respiratory infections.

Pivot will combine its patented RTIC™ cannabis powder technology with the TriVair™ delivery system to provide a rapid onset effect for patients and consumers in markets where regulations permit. Pivot’s Product Formulation Team, led by Dr. Leonid Lurya in Israel, has initiated testing to evaluate, modify and test formulations that achieve the desired particle size for delivery by the TriVair™ device.

IP Med’s Vice-President, Mr. Ben Isaacs, comments that “I am excited to partner with the team at Pivot Pharmaceuticals. With their product development and commercialization experience, and impressive RTIC powdered cannabis technology I am confident that the TriVair™ device will provide a safe and effective way for the delivery of cannabinoids into patients.”

Dr. Joseph Borovsky, Pivot’s Executive Vice President, Product Development, stated “We are very pleased to add the TriVair™ device to Pivot’s product line and expand the range of delivery systems for cannabinoids. This pre-loaded and single-use device, will be a disruptive technology and provide solutions for patients with special medical needs.”

Pivot’s Chief Medical Officer, Dr. Wolfgang Renz commented “Pivot continues to grow its portfolio of patented technologies specifically for the formulation and delivery of cannabinoids. We are very excited about the unique opportunity this differentiated product presents for patients seeking an alternative method to traditional cannabis practices. Upon the completion of our compatibility testing, Pivot will have the world’s first nasal and pulmonary powdered cannabis device for quick onset and use in the medical field. This combination product may be well suited for managing such indications as sleep disorder, migraine, late-stage cancer pain, and address opioid withdrawal.”

TriVair™ Nasal Device (CNW Group/Pivot Pharmaceuticals Inc.)

TriVair™ Pulmonary Device (CNW Group/Pivot Pharmaceuticals Inc.)

TriVair™ Nasal/Pulmonary Combination Device (CNW Group/Pivot Pharmaceuticals Inc.)

TriVair™ In Use (CNW Group/Pivot Pharmaceuticals Inc.)

About IP Med Inc.

IP Med partners with (physician) inventors, academic institutions and pharmaceutical companies to bring their concepts to market: We create, develop (design and engineer), patent, prototype, build proof of concept, commercialize and/or monetize unique and innovative technologies and compounds in efficient and cost effective ways. IP Med’s founders bring 35 + years of success and experience in strategic planning and marketing for the pharmaceutical and medical product industries; working with top-tier companies including Pfizer, Wyeth, Eli Lilly, Merck, AstraZeneca and GlaxoSmithKline just to name a few. IP Med maintains close relationships with a vast network of executives within major companies in the medical arena; including pharmaceutical, biotech and medical device companies. For more information please visit www.ipmedinc.com

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, IP Med Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, statements with respect to internal expectations, including with respect to the TriVair™ device, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/pivot-signs-option-agreement-to-acquire-licensing-rights-to-patented-trivair-nasal-and-pulmonary-drug-delivery-system-for-its-rtic-ready-to-infuse-cannabis-powder-300657112.html

SOURCE Pivot Pharmaceuticals Inc.

 

Source: PR Newswire (May 31, 2018 – 3:05 AM EDT)

The post Pivot Signs Option Agreement to Acquire Licensing Rights to Patented TriVair™ Nasal and Pulmonary Drug Delivery System For Its “RTIC” Ready-To-Infuse-Cannabis Powder appeared first on CannabisFN.

Delta 9 Q1 Fiscal Results Show Increased Revenue and Profits

Written by Ryan Allway on

WINNIPEG, May 31, 2018 /CNW/ – DELTA 9 CANNABIS INC. (TSXV: NINE) (“Delta 9” or the “Company”) today announced the Company’s Q1 fiscal results.

Delta 9 is a producer of legal cannabis trading on the TSX-V under the symbol NINE. (CNW Group/Delta 9 Cannabis Inc.)

Highlights of the Company’s operations include:

  • As of March 31, 2018 the Company had 21,693,847 in working capital on hand;
  • The Company reported revenue of $332,107 from the sale of dried cannabis, an increase of 225 per cent over the same period in the prior year;
  • The Company also reported increased profits for the quarter at $202,695, an increase of 644 per cent over the same period in the year prior.

Delta 9 also undertook significant investments during the reporting quarter, including an investment of $1425,852 in the expansion of its cultivation facilities in Winnipeg by building and installing more of the Company’s proprietary, self-designed grow pods, and an investment of $3 million to acquire a 50 per cent equity interest in the Delta West cannabis production facility in Calgary, Alberta. The Delta West facility is a jointly owned venture with Westleaf Cannabis, but will operate under the Delta 9 license.

Delta 9’s management also reported on several successful ventures during the reporting period, as follows:

  1. Delta 9 and Canopy Growth jointly acquired the conditional license to build and operate retail cannabis stores in the Province of Manitoba, one of only four proponents to be awarded that license;
  2. The Company entered into an export agreement to Germany with Global Group Kalapa and CanPharma, both of which are early pioneering firms working in the area of medical cannabis in Europe;
  3. The Company signed a Memorandum of Understanding for a Supply Agreement with Sundial Growers Inc. for 8,000 kilograms of cannabis, in order to secure supply for its growing retail operations in Alberta and Manitoba;
  4. Delta 9 co-developed a hemp beer called Legal Lager with Fort Garry Brewing Company in Manitoba, and has a non-alcoholic cannabis beer (with THC) in development, subject to approvals by the federal government;
  5. Delta 9 completed negotiations to buy out the land on which its production facilities are located, securing a significant acreage suitable for expansion, at a price of $6,250,000. Delta 9 is currently developing a Cannabis Campus that will be among the largest production facilities in the world. The option to buy the property is expected be executed in Q3 once the subdivision of the land has been approved by the City of Winnipeg.

In addition to the activities completed by management in Q1, Delta 9 reports that in early April the Company signed a Letter of Intent to become a Preferred Supplier with Pharmasave Drugs Ltd., a leading pharmacy chain with approximately 650 member-owned outlets across Canada.

CEO John Arbuthnot says the results of the Company’s business activity in Q1 came from a deliberate plan to position Delta 9 for the upcoming legalization of cannabis.

“We believe that the key element for success in the coming legal market is access to distribution and the ability to retail our products,” Arbuthnot says. “For this reason, we focused less on client acquisition under the Access to Cannabis for Medical Purposes Regulations (ACMPR), which we did not see as a long term driver of profits, and instead have focused very heavily on positioning Delta 9 for distribution and sales under the upcoming legal regime for recreational.

“Our success in acquiring the retail license in Manitoba, in working closely with Pharmasave, and acquiring an export agreement to Germany are all the result of our focus on market access. We feel that focus will pay off when legal sales begin, and that Delta 9 is among the best placed companies in Canada in terms of market access.”

About Delta 9 Cannabis Inc.
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) Delta 9’s expansion plans; (ii) Delta 9’s production of cannabis; (iii) approvals for Delta 9’s production facilities by Health Canada; (iv) demand for Delta 9’s products; and (v) Delta 9’s cost to produce its grow pods. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9’s currently contemplated expansion and development plans may cease or otherwise change, Delta 9’s production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9’s products may be lower than anticipated, Delta 9’s cost to produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Delta 9 Cannabis Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2018/31/c3652.html

Gary Symons, Director of Communications, communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

 

Source: Canada Newswire (May 31, 2018 – 4:30 AM EDT)

The post Delta 9 Q1 Fiscal Results Show Increased Revenue and Profits appeared first on CannabisFN.

BlissCo Cannabis Corp Announces Listing on Frankfurt Stock Exchange

Written by Ryan Allway on

VANCOUVER, May 31, 2018 /CNW/ – BlissCo Cannabis Corp. (FRA: GQ4B) (CSE: BLIS), (“BlissCo”) is pleased to announce that the company is now listed on the Frankfurt Stock Exchange and is trading under the symbol GQ4B.

35% of the world’s investment capital is represented on the Frankfurt Stock Exchange. This new listing will provide BlissCo with broader access to international investors in Europe and beyond.

“The BlissCo team is committed to building value for our investors, partners, team and customers. By listing on the Frankfurt Stock Exchange, we are making it easier for international investors to participate in our growth. The Frankfurt Stock Exchange is the leading exchange in the German and European markets,” said Damian Kettlewell, BlissCo CEO.

The Frankfurt Stock Exchange is used by over 250 trading institutions and ranks third globally in trade volume, following only the New York Stock Exchange and NASDAQ.

About BlissCo Cannabis Corp

BlissCo (CSE: BLIS) (FRA: GQ4B) earned its Access to Cannabis for Medical Purposes Regulation ACMPR License to Cultivate on Thursday, March 29, 2018. BlissCo’s ACMPR facility in Langley, B.C. is designed to be a high-volume packager, processor and distributor of premium medical cannabis and adult use cannabis when it is legal in Canada, which is currently anticipated to be August 2018 at the earliest. BlissCo has a two-year supply agreement with The Supreme Cannabis Company Inc (TSX.V: FIRE) to purchase 3,000 kilograms of premium whole dried cannabis flower.

BlissCo will apply to expand its licenses to include medical cannabis oil production and medical cannabis sales in Q2 2018. BlissCo will focus on high volume sales opportunities in the regulated medical use and adult use cannabis market in Canada when it is legal and is pursuing expansion opportunities in international markets.

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

SOURCE BlissCo Cannabis Corp.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2018/31/c6395.html

Damian Kettlewell, CEO, (604) 484 9119, ext. 3, damian.kettlewell@blissco.comCopyright CNW Group 2018

 

Source: Canada Newswire (May 31, 2018 – 5:00 AM EDT)

The post BlissCo Cannabis Corp Announces Listing on Frankfurt Stock Exchange appeared first on CannabisFN.

Future Farm to Showcase Company Growth at the 8th LD Micro Invitational & Announces Research Report by RB Milestone Group

Written by Ryan Allway on

ANCOUVER, British Columbia, May 31, 2018 /PRNewswire/ —

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (CSE: FFT.CN) (OTCQX: FFRMF) is pleased to announce that it will be presenting at the 8th annual LD Micro Invitational on Monday, June 4th at 4 PM PT/ 7 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Thomas L. Barrette, the Company’s General Counsel, will be presenting and meeting with investors.

“We are grateful to LD Micro for including us in this great conference and look forward to sharing our exciting story with those attending,” says Mr. Barrette.

Mr. Barrette will be highlighting the Company’s Q1 accomplishments including new partnerships and plans for future strategic growth. He will also be discussing the status of current projects under development.

The conference will feature 230 companies in the small-cap / micro-cap space and will be attended by over 1,000 individuals. View Future Farm’s profile here: https://www.ldmicro.com/profile/FFRMF.

If you would like to schedule a meeting with Future Farm, please contact Trevor Brucato, Managing Director of U.S. based consulting firm RB Milestone Group, LLC (“RBMG”), at tbrucato@rbmilestone.com.

The Company also announces that an analyst’s research report has been released by RBMG. The report provides an in-depth overview of the Company’s divisions: cultivation/vertical farming, cannabis extraction and processing, cannabis retail, and technology. It also provides an investment rationale, SWOT analysis, and an overview of the dynamics of the medical cannabis industry and LED industry trends.

A copy of the research report can be accessed by visiting the homepage of Future Farm’s corporate website (https://futurefarmtech.com) or by contacting Trevor Brucato.

On behalf of the Board,
Future Farm Technologies Inc.
William Gildea, Chairman and CEO

About Future Farm Technologies Inc. 

Future Farm is a Canadian company with holdings throughout North America including California, Massachusetts, Florida, Maine, Puerto Rico and Newfoundland. The Company’s mission is to advance sustainable agriculture through production of wholesale and retail cannabis products, including hemp. As a leader in its field, Future Farm is committed to using only the highest quality processes and products. Towards this goal, the Company acquires or partners with licensed cannabis operators, and acquires or develops leading technologies in cannabis production, breeding, genetics, and Controlled Environment Agriculture (CEA). Future Farm’s scalable, indoor CEA systems utilize minimal land, water and energy resources. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit http://www.ldmicro.com for more information.

About RB Milestone Group, LLC

RB Milestone Group (“RBMG”) is a U.S. based consulting firm that specializes in assisting small and venture-stage companies with enhancing: corporate strategy, business development, investor awareness, market intelligence and research. RBMG partners with clients internationally and across a wide range of industry segments, including: mining, energy, oil & gas, technology, cleantech, healthcare, consumer goods, and professional services. Staff specialists have diverse sector knowledge centered on capital markets.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

For further information, contact:
William Gildea
Chairman and CEO
+1(888)387-3761

Investor Contact: 
Trevor Brucato
Managing Director
RB Milestone Group, LLC
tbrucato@rbmilestone.com

SOURCE Future Farm Technologies Inc.

 

Source: PR Newswire (May 31, 2018 – 8:00 AM EDT)

The post Future Farm to Showcase Company Growth at the 8th LD Micro Invitational & Announces Research Report by RB Milestone Group appeared first on CannabisFN.

James E. Wagner Cultivation: A Mix of Legacy and Innovative Technology, Going Public Soon

Written by Ryan Allway on

Canada’s cannabis industry could reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis later this year. While there are over 100 licensed producers, many analysts believe that there could be a shortfall in production as the country’s domestic market and export opportunities continue to grow, which creates numerous opportunities for investors to profit in the space.

James E. Wagner Cultivation is a unique opportunity in the space that is built upon a long family reputation dating back to the 1920s and 1930s in the tobacco industry. Following the original James Wagner’s legacy, the family-owned business became a licensed producer of medical cannabis under Health Canada’s ACMPR program last year. The company plans to go public in the very near future.

Click here to get a Going Public Alert and see the company’s investor presentation.

Rapidly Expanding Operations, Proprietary Aeroponic Grow System

While James E. Wagner Cultivation, or JWC, started as a small family enterprise and maintains that familial feel, the company has much larger ambitions. Since receiving its initial cultivation license in January 2017, the company has grown consistent, high-quality medical cannabis at its 15,000 sq. ft. facility in Kitchener, Ontario using its patent-pending GrowthStorm™ aeroponic growing technology.

GrowthStorm™ aeroponics at work

The GrowthStorm™ system begins with a cloning process that costs as little as ten cents per cutting with high yields and no contaminants. The plantlets are then inserted into a modular hydroponic growth system based on aeroponic techniques developed at NASA where plant roots hang within an enclosure. Fast and efficient machine-assisted hand-trimming systems along with innovative drying systems round out the process to yield sale-ready products.

In February 2018, the company entered into a lease agreement for a second 345,000 sq. ft. facility in the same city. The company is actively working on a phased expansion of the second facility, which is expected to significantly increase its production rate. Management expects the second facility to be up and running in Q3 of 2018, and to complete the whole facility in Q3 of 2019. JWC believes that, upon completion, the new facility will be the largest aeroponic operation in the world.

JWC 345,000 square foot facility

In addition to its in-house efforts, the company entered into a strategic partnership with Canopy Growth Corp. (TSX: WEED) and its strategic investment arm, Canopy Rivers Corporation. The partnership provides the company with access to high-quality genetics sourced from around the world, industrial scale cannabis oil infrastructure, and a rigorous quality assurance program, as well as online distribution through CraftGrow and Tweed Main Street.

Click here to get a Going Public Alert and see the company’s investor presentation.

Near-term Plans to Go Public

James E. Wagner Cultivation entered into a business combination agreement with AIM1 Ventures Inc. (TSX-V: AIMI) in April 2018, which paves the way for JWC to go public in Canada’s TSX Venture exchange. Under the terms of the deal, JWC will complete an over-subscribed brokered private placement financing for $18.5 million in gross proceeds.

Since the industry’s humble beginning, licensed producers have grown to achieve multi-billion dollar valuations. Canopy Growth Corp. (TSX: WEED) is the largest licensed producer with a market capitalization of more than C$7 billion, but there are at least ten companies in the space with market capitalizations of more than C$1 billion. Canada’s legalization of adult-use cannabis later this year could pave the way to even greater valuations over the coming years.

Investors interested in the space may want to consider companies that are preparing to go public since they aren’t already valued at lofty multiples. In particular, investors may want to consider a company’s operating history, financial performance, and proprietary technologies when evaluating opportunities. Established companies with barriers to entry often represent better opportunities than development-stage companies with higher execution risk.

Looking Ahead

James E. Wagner Cultivation represents a compelling investment opportunity in Canada’s burgeoning cannabis industry. With in-house production ramping up next year and agreements in place with Canopy Growth, the company plans to produce upwards of 30,000 kilograms per year in its combined facilities. These products will be sold into Canada’s rapidly growing market as well as in potential export markets around the world. Interested investors are encouraged to keep an eye out as the company plans to go public in the very near future.

Click here to get a Going Public Alert and see the company’s investor presentation.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post James E. Wagner Cultivation: A Mix of Legacy and Innovative Technology, Going Public Soon appeared first on CannabisFN.

Valens GroWorks Capitalizing on the Cannabis Extracts and Products Surge in Canada

Written by Ryan Allway on May 30, 2018

As the cannabis industry matures throughout North America and across the globe, some trends are solidifying in terms of the preferred method of intake. Notably, smoking cannabis flower is becoming less prevalent while the use of extracts and oils (and products based on those) is on the rise. With Canada on the verge of legalizing cannabis for adult-use, the country is sort of a test case for market dynamics. The most recent data released by Health Canada shows sales of cannabis oil on par with dried marijuana as of April 2017, but exceeding dried sales by almost 50% as of December 2017.

Valens GroWorks Corp. (CSE: VGW) is a multi-licensed company, based in the Okanagan Valley of British Columbia, that recognizes this trend toward oils and derivatives and is uniquely positioned to capitalize on it. Valens is covering all of the bases, with a late-stage licensed producer application pending; two dealers licenses that allow for research, cultivation, and product development; high volume extraction capability; and a distribution deal in place with Canopy Growth Corporation (TSX: WEED).

Valens GroWorks grow room

The Valens Licenses and Facilities

Valens GroWorks consists of three subsidiary companies. The first, wholly-owned Valens Agritech Limited, holds a dealers license from Health Canada that allows for cannabis cultivation, processing, oil production, and sales of those oils through licensed producers. Currently housed in a 17,000 square foot cultivation and research center, the company is in the late stages of its application to become an ACMPR licensed producer as well.  

Valens AgriTech utilizes state-of-the-art CO2 extraction equipment that efficiently yields pure extracts with minimal post-processing requirements. With the recent addition of two more extraction machines, the company can now process 6,500 kg/month of cannabis raw material. The oils produced in the process can initially be sold through Valens’ agreement with Canopy Growth, offering near-term revenue while the company expands its operations and develops its own distribution networks. Alongside the revenue opportunity, Valens’ presence in Canopy’s CraftGrow distribution network allows the company to develop early brand recognition. This is especially important in the early stages of recreational legalization.

Valens CO2 extraction equipment

Valens AgriTech recently completed its own first harvest with tremendous results. Growing a strain of cannabis expected to yield 18-19% THC content, the company reported crops yielding about 24% THC. The company credits its Master Growers’ expertise, advanced growing facility, and overall commitment to providing credible products, and the results show great promise as the foundation for creating premium oil-based products.

The second wholly-owned subsidiary, Supra THC Services, also holds a dealer’s license from Health Canada, though this one is a bit different. Supra doesn’t cultivate its own cannabis, but offers commercial testing and analytical services. Supra recently moved into the Valens AgriTech facility, which is in the process of being GMP-certified. This certification is important, because with it (and the appropriate export licenses) the company would be able to sell its products in even the most demanding regulatory environments.

Supra offers testing and analytical services to individuals and licensed producers, offering another near-term revenue source. As the cannabis industry expands, and in light of a number of pesticide-based product recalls in Canada, the need for accurate third-party testing is great now and will only grow in the future. In a further indication of Valens’ commitment to quality science, the company has also teamed with research and laboratory giant ThermoFisher Scientific to create a Centre of Excellence for Plant Based Medicine Analytics in the Valens facility.

The third wholly-owned subsidiary, Valens Farms, was recently formed to commercially produce premium quality cannabis. The company recently entered into a partnership with Kosha Projects Inc. The companies have broken ground on a 400,000 sf cannabis production facility in Armstrong, BC. The city has already approved the construction of around 850,000 sf, giving Valens Farms room to expand even further should the need arise. When it’s all said and done, the two companies will each have a 50% interest in the subsidiary.

The Bigger Picture

All of the pieces fit nicely into the Valens puzzle, comprising a company that offers a more complete picture than many more well-known cannabis enterprises. Valens’ ultimate goal is to extract and sell its own premium cannabis and cannabis-derived products sourced from cultivation facilities that they own, operate or partner with to ensure the product is consistent and of superior quality. The receipt from Health Canada of the license to produce, and the subsequent license to sell, is certainly key in allowing Valens to control all aspects of its vertically integrated operation. But even prior, the company is in a unique position to capitalize on the booming Canadian (and even international) cannabis industry.

Through its licensed subsidiaries, Valens can cultivate its own cannabis to fuel research and development of products. These products can be developed internally, or on behalf of third parties like licensed producers, pharmacies, and natural health companies. Examples of cannabis-derived products, some of which have yet to be legalized in Canada, include edibles, beverages, personal care products, and nutraceuticals.

Valens cannabis extract

Valens is currently extracting pure cannabis oils for research to perfect its own products (upwards of 20 types) that could then be sold initially through the extensive CraftGrow network, including tweedmainstreet.com, and through other distribution channels as the company develops them. Valens currently has 100 kilos of extract on site, giving the company plenty of raw material for the scientific development and validation of its formulations prior to hitting the market.

Meanwhile, the company is establishing itself as a leader in lab services and analytics. Near-term revenue streams like this are invaluable to Valens as it looks to establish its brand and expand operations, potentially decreasing the need to raise money along the way. As it stands now, the company has sufficient funds to move forward with its business plan and has no plans for financing in the near future. Keep an eye out for future developments as there are plenty of potential catalysts on the Valens GroWorks horizon.

The post Valens GroWorks Capitalizing on the Cannabis Extracts and Products Surge in Canada appeared first on CannabisFN.

BlissCo: New Public Licensed Producer Focused on Distribution

Written by Ryan Allway on

As the landscape of Canadian licensed producers becomes a bit more crowded, there are some characteristics that may help identify those with a better chance of succeeding than others. Partnerships, licenses, management, and location are among these differentiating factors, and BlissCo Cannabis Corp. (CSE: BLIS, FRA: GQ4B ) is one of the young producers with a strong resume in all of these areas. With adult-use legalization on the horizon and the legal cannabis market set to explode, BlissCo looks ready to carve out its niche in the multi-billion dollar industry.

Recently Licensed, Recently Public

BlissCo went public through a reverse merger and began trading on March 2, 2018 following an oversubscribed financing of about C$5.6 million. That financing helped the company put some finishing touches on its level 10 security production facility in the Metro Vancouver area, and Health Canada granted the company its ACMPR cultivation license on March 29. BlissCo is in the process of applying for a cannabis oil extraction license, and anticipates applying for a sales license this summer.

The Supreme Cannabis Company (TSXV: FIRE) participated in the financing to the tune of C$3 million. The investment gives Supreme an approximate 10% ownership of BlissCo, and comes along with a supply agreement for dried cannabis which will enable BlissCo to begin sales and distribution immediately following receipt of its sales license. This 3,000 kilo, two year supply agreement with Supreme has the potential to generate over C$25 million in medical cannabis revenue for BlissCo.

Not All LPs Need Huge Production

Many licensed producers have undertaken massive expansion projects over the last year or so, spending huge amounts of capital to increase production ahead of full legalization. The approach makes sense in light of the anticipated initial shortfall of supply for the greatly expanded market, but comes with its own set of risks. These include problems associated with scaling agricultural production on an industrial level, like crop failure and quality control. They also include issues that could arise as a result of market forces, like the eventual commoditization of cannabis flower causing a significant price decrease.

BlissCo, while not eschewing its own production capacity, is taking a different approach. The company is more focused on packaging, branding, and distribution. Its facility is designed from the ground up as a center for high volume extraction, processing, packaging and distribution in addition to its cultivation capacity. Set in the Metro Vancouver area, it is ideally located for efficient and low-cost distribution.

The supply agreement with Supreme allows BlissCo to jumpstart its operations and revenue while it scales its own production. BlissCo hopes to have a sales license by September, which is coincidentally about the time that adult-use is anticipated to be legalized. With supply assured, the company should be able to hit the ground running at that point.

“Over the past year, we have revised our business model to concentrate on our core strength: in-province cannabis distribution,” said Damian Kettlewell, CEO and Founder of BlissCo. “British Columbia will be a competitive retail market where quality will be a differentiating factor. Our focused business plan has allowed us to avoid the time and capital commitments of developing massive cultivation infrastructure, and instead pursue partnerships with leading quality-focused cultivators such as Supreme Cannabis’ 7ACRES.”

BlissCo recently purchased CO2 cannabis oil extraction equipment that it can use, when properly licensed, to make high quality extracts and eventually products (like edibles, creams etc.) based on those extracts. Recent data from Health Canada shows sales of cannabis oil as of April 2017 on par with dried flower. But demand for quality cannabis oil is on the rise. Fast forward to the most recent data from December 2017, and cannabis oil sales are almost 50% higher by volume than dried flower sales. BlissCo recognizes this explosive trend and is positioning to take advantage. As of now, only 6 of the 22 licensed producers in British Columbia are approved to produce and sell oil.

Management Offers Varied Experience

CEO Damian Kettlewell has a deep background in alcohol sales and distribution that should serve BlissCo exceedingly well as the cannabis model evolves. He is a director of British Columbia’s Alliance of Beverage Licensees (ABLE BC) and was also involved in a recent public-private partnership called the Responsible Marijuana Retail Alliance of BC. Prior to founding BlissCo, he was a partner for 11 years with a major BC liquor store chain. Undoubtedly Mr. Kettlewell knows how to distribute and sell adult-oriented products in British Columbia.  

The public side of the company is in good hands with CFO Rob Kang. He is well-versed in all aspects of the regulatory side, with over 20 years of experience at TMX Group prior to joining BlissCo. Shawn McDougall heads up the production side with over 10 years of experience as a Health Canada certified cultivator. Vipin Vikraman adds more than 10 years of experience in quality assurance, with a background in the packaged foods, poultry, and dairy industries.

The Upshot

Developments have been coming fast and furious for BlissCo, as the company has gone public, been licensed, inked a major partnership, and begun cultivation all in the last three months. There are plenty of potential catalysts in the next few months as well, with more licenses anticipated and the pending legalization of cannabis in Canada. BlissCo bears watching as it is taking a slightly different tack from many licensed producers. By focusing less on production and more on creating a processing, distribution, and branding company, BlissCo appears positioned to deliver value both in the near term and over the long haul.

Forward-Looking Statements

This article contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the words “may”, “will”, “in the process” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This article contains forward-looking statements and assumptions pertaining to the following: the ability to execute on the strategic plans and the impact on future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis, the generation of revenue from the sales of cannabis, the anticipated benefits of the location of the company’s facilities, the production of products based upon extracts, the relevance of management’s experience to the cannabis model, the ability of the company to deliver value and other objectives. Actual results achieved may vary from the information provided as a result of numerous known and unknown risks and uncertainties and other factors. It is believed that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. Neither we nor the company undertake to update these forward-looking statements, except as required by law.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post BlissCo: New Public Licensed Producer Focused on Distribution appeared first on CannabisFN.

CFN Media’s Exclusive Interview With Lexaria Bioscience CEO Chris Bunka

Written by Ryan Allway on

Despite cannabis remaining illegal in most parts of the world, cutting-edge research into the plant’s profound abilities continue to expand. Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) is paving the road in terms of cannabinoid delivery research and development. Their patented DehydraTECH™ technology allows for the oral consumption of cannabinoids without the typical scent and flavor, while also avoiding first-pass liver metabolism. Nuka Enterprises LLC, one of the largest edible manufacturers in the world, recently signed a 10-year agreement with Lexaria in order to continue bringing delicious and effective 1906 chocolates to consumers across the globe.

CFN Media spoke with Lexaria CEO Chris Bunka at the recent MJBizNEXT Conference in New Orleans to learn more about the firm’s innovation and their plans to dramatically change the way people think about cannabis.

CFN:  How does your DehydraTECH™ delivery method work?

Chris Bunka:  We believe that infused foods should taste more like food and less like marijuana. Our consumers find their coffee tastes a bit more like coffee and less like cannabis, and additionally notice that the cannabinoids take effect faster, and they feel a different type of effect than the typical edible. For medical patients who medicate often, that difference means a lot.

Our tech allows cannabinoids to avoid first pass liver metabolism, and that’s why we have some dramatic biochemical differences. We take a cannabinoid and we kind of “glue” it to oleic acid, which is a sub-component of sunflower oil or olive oil; both long chain fatty acids.

That “gluing” is really important, and sunflower oil is a really good choice because it has a neutral taste. If you tried olive oil, you’ll taste plant, it tastes different. So, when we “glue” the THC or the CBD or the terpenes to the oleic acid, you get that neutral flavor, and it’s pretty dramatic in most things. We put it in coffee, tea, water, white wine, beer, protein bars, cookies, chocolates, candies, gummies; we put it into so many things. Basically, about 99 percent of the strong flavor is gone, and you don’t have to add any sugar, and you don’t have to add any chemicals.

When you swallow food, it goes into your stomach. Whatever doesn’t get absorbed obviously gets excreted as waste, but as it passes through the intestine, there’s all these opportunities to get absorbed across the intestinal wall. Well, the intestinal wall is not just a filter. It’s not just this physical barrier. It’s actually a very highly communicative, two way, sensing organ. There’s sensing apparatus all over it, and those senroy cells are looking for what is it that’s here. “Is it a fat? What kind of fat? Is it a protein? Is it sugar? What kind of sugar?”

Depending on all sorts of different stuff, which one of those receptors are being triggered, different signals get sent to your pancreas and different biomes are created to help pull those nutrients across the intestinal wall. Your body is actually actively trying to pull those nutrients in. Well, oleic acid is like the wonder molecule as far as your intestine is concerned. It’s one of the only things you can swallow that does not get passed through the intestinal wall and then delivered to the hepatic vein that goes to the liver for first pass liver absorption.

CFN:  Tell us about your intellectual property?

CB:  Our patent portfolio is super strong. Last December, we received our first patent from the U.S. Patent Office on nicotine and the ibuprofen and aspirin delivery as well as the cannabinoids. We’re in the active investigation phase in the EU, Canada, China, Japan, and India right now, so we’ll probably have additional progress there soon. Our IP lawyer has joined our advisory board because he’s really fascinated with what we’re doing, and he has a PhD in neuroscience, as well as being a patent attorney.

We’re filing new patent applications all the time. So, in the industry, I know that GW certainly has more patents and patent applications than we do, and I know that Canopy up in Canada is pretty much neck and neck with us. They’re in the 30-40 patent application range, and so are we. Maybe we’re a little ahead by numbers, but I’m almost certain that Canopy, for example, has no granted patents, and I know that GW only has a few, and we are kind of neck and neck with them also. We are right at the leading edge in the world for patent applications and patent granting, and IP in the cannabis sector.

CFN:  What types of exciting discoveries have you been making in your research?

CB:  We conducted a study recently on rats, using nicotine as an active ingredient. Blood tests showed we are getting an average of 50 percent more nicotine into the rats’ blood compared to rats in the control group. We said okay, well, that’s good. So, if I had 10 milligrams of THC, it’ll have the effect of 15 compared to not using our tech. We also took kidney, liver and brain tissue samples, and found in the brain we had 560 percent more nicotine with our tech than without. That is a profound discovery because frankly, we don’t know exactly how we did it. There was 50 percent more level in the blood plasma and so you would naturally think, “Okay, there’s 50 percent more available to penetrate to receptors anywhere”, but instead it increased 11-fold: 50 percent to 550.

We already knew that our tech crosses the intestinal wall way more effectively but based on these results, we’re wondering if affects blood-brain barrier transmission as well. If it does, this has the potential to have profound ramifications for pharmaceuticals and biotech, and not just cannabis. Here is research that is being done, all originating out of the cannabis industry, for the cannabis industry, that could have profound public health consequences for applications from cancer, brain tumors, the ability to be able to deliver to the brain substances that right now can’t get across that barrier.

That’s massive potential but it is early, early, early days, and we’ve done one study, and it’s on rats, it’s not humans; so there’s a lot of area we still need to grow our knowledge. Still, it’s a profoundly unusual and unexpected result, and we’ve talked to a number of leading PhD researchers around the world in the three weeks since we’ve published that, and none of them can explain it. We’re going to repeat the study and do a larger population of animals. We only had 12 rats in that study. In the next one, we were thinking of doing 30, or 40, or 50. That would give you more robust data and additional opportunities. If it repeats, I can’t tell you how big this is to us.

CFN:  Why should potential investors consider Lexaria?

CB:  Unlike some companies, we really do actually respect our shareholders. I don’t go for this new modern idea of issuing hundreds and hundreds of millions of shares because there is a big cost to issue 100 million shares which will raise a lot of money in the process: and yes it can help you build your business and yes it can help you to preserve your jobs – it can do all those things. That’s all really, really good: but you’ve completely skewered your investors because you’ve issued so many shares. How much additional value are you going to have to create to justify that market cap? If you look at us, our share count has probably grown among the least on the continent in the last three to four years compared to other companies in our sector. We’re at about 71 million shares outstanding today. That’s still really low compared to most of the others.

Unlike some of these other companies that need tens of millions of dollars to operate and grow before they hit cash-flow positive or profitability, our burn rate is super, super low – so a couple million dollars goes a long way with us, and our cash-flows are increasing, because we’re a licensing and R&D company. One of the biggest considerations of all the companies that you can think of that are public in the cannabis space – I don’t think there’s another one that comes remotely close to us in this way – is to be able to match the applicability of our business model outside of cannabis. Our valuation has gone up by close to 2000 percent in the last couple of years because our tech applies to several different sectors.

One of the main things I want people to realize is: this is for real. This is not a game to the management of Lexaria. None of us are interested in some quick market appreciation in order to dump a million bucks worth of stock. I started buying stock in this company in 2005, and I have never sold a share. In 2014-15, I bought about another 6 million shares out of the market, just like anyone else can, and I’ve never sold one of those shares, either. They’re all sitting in my accounts. I know it’s so corny, but we are actually interested in changing the world. We think we can slow down disease, we think we can save lives, we think we can make cannabis more acceptable for the general population and take the stink factor out, and that’s all positive stuff.

We ARE going to make the world a better place and our accomplishments so far are nothing compared to what we have planned.

Please visit the company website: https://www.lexariabioscience.com

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post CFN Media’s Exclusive Interview With Lexaria Bioscience CEO Chris Bunka appeared first on CannabisFN.

Koios Launches Clinical Trials to Study Efficacy of Drinks

Written by Ryan Allway on

VANCOUVER, May 22, 2018 /CNW/ – Koios Beverage Corp. (CSE: KBEV; OTC: SNOVF) (the “Company” or “Koios“), which makes brain healthy beverages that can improve cognitive function, is pleased to announce it has entered into an agreement with NeuraPerformance/Neuroptimize Brain Center whereby NeuraPerformance/Neuroptimize will perform full clinical brain scans on Koios users.

NeuraPerformance/Neuroptimize is the go-to brain lab and physiotherapy clinic for Colorado’s elite athletes, including the Denver Broncos football team. The centre specializes in brain mapping, brainwave optimization, enhancing sports performance, baseline concussion testing and treatment.

NeuraPerformance/Neuroptimize will also stock and sell Koios beverages in the future, at its numerous locations.

“Our respective companies have a shared vision and passion for mental health and performance,” said Rachel Ragsdale, director of brain mapping, neurofeedback and counselling at NeuraPerformance/Neuroptimize. “Helping them demonstrate the efficacy of their products is something we truly look forward to doing.  Additionally, adding their products to our platform of services creates tremendous value for our clients and the people we are trying to help.  Mixing technical science with their stellar products is a win for everyone.”

The full clinical brain-scan study may provide evidence that Koios products may enhance cognition over the long term and help the Company fine-tune its beverages’ performance.

“For many years we have been looking for the right partner and platform to test our technologies and products,” said Chris Miller, CEO of Koios. “Not only will this clinical trial further substantiate our product formulation, but the data collected will pave the way to creating better technologies within our portfolio, and fulfiling our mission of creating some of the most functional organic products that support and enhance brain health and performance.”

The initial results of the study are expected in July.

About the Company’s Business

The Company, through its wholly-owned subsidiary Koios, Inc., is an emerging functional beverage company which has an available distribution network of more than 2,000 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.  Together these distributors represent more than 80,000 bricks and mortar locations across the United States – from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets.  Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.  Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.  Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

Koios is one of the only drinks in the world to infuse its products with MCT oil.  MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/

On behalf of the Board of Directors of the Company.

KOIOS BEVERAGE CORP.

“Chris Miller”
Chris Miller, CEO and Director

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements with respect to the statement that the clinical scans will yield scientific evidence regarding the efficacy of the Company’s products and enable the Company to improve its products; and the statement that the initial results of the clinical scans are expected in July. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: (i) adverse market conditions; (ii) the inability of the Company and NeuraPerformance/Neuroptimize to complete the clinical scans on time or at all; and (iii) that the clinical scans, if completed, may not yield scientific evidence of the efficacy of the Company’s products. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s documents filed from time-to-time with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Koios has not conducted any scientific studies on the effects of Koios’ products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’ products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’ products on an individual’s health and wellbeing.

SOURCE Koios

View original content: http://www.newswire.ca/en/releases/archive/May2018/22/c8798.html

Paula Arab, Media and Investor Relations Strategist, paula.arab@koiosbeveragecorp.com, 403-889-9128Copyright CNW Group 2018

The post Koios Launches Clinical Trials to Study Efficacy of Drinks appeared first on CannabisFN.

Segra Signs Agreement with Agripharm for Large-Scale Cannabis Plant Micropropagation Services

Written by Ryan Allway on

VANCOUVER, May 30, 2018 /CNW/ – Segra International Corp. (“Segra”) is pleased to announce that it has finalized an agreement with Agripharm Corp. (“Agripharm”) to incorporate Segra’s cannabis tissue culture micropropagation technology into Agripharm’s cannabis production systems, enabling Agripharm to rapidly scale up its production of disease-free, genetically verified cannabis plants.

“Segra is thrilled to assist Agripharm in scaling up production while maintaining the highest possible quality standards,” said Segra’s CEO and cofounder, Todd McMurray. “This is another huge milestone for Segra toward our goal of becoming the premier global brand in cannabis micropropagation.”

Working with Agripharm’s team, Segra will construct a tissue culture lab at the Agripharm facility in Creemore, Ontarioin order to prepare numerous cultivars for the micropropagation process. Subject to performance milestones, production will then move to Segra’s dedicated cannabis micropropagation facility for mass production once construction and licensing are complete.

“Segra’s cannabis tissue culture technology will be an essential component of our cultivation process,” said Green House Seed Co. founder, Arjan Roskam. “As we tap into Green House Seed Co.’s award-winning genetics library, our number one priority will be ensuring that we can reliably reproduce the strains that consumers have come to love. We believe that using micropropagation will be a big leap forward in ensuring we can continue to deliver genetically accurate and disease-free products to market.”

“The benefits of integrating micropropagation into industrial-scale agricultural businesses are well documented; we expect this partnership to drive meaningful cost improvements while also improving product quality and increasing production efficiencies,” said Agripharm CEO and cofounder, Peter Miller. “This was a no-brainer.”

About Agripharm

Agripharm Corp. is an ACMPR-licensed, 20,000 sq. ft. indoor growing facility based in Creemore, Ontario. The company is operated through a joint venture between Canopy Growth, Green House Holdings North America Inc. (Strainhunters, Green House Seed Co., King of Cannabis, and GH Medical), and Organa Brands (O.penVape, Magic Buzz, Bakked, and District Edibles).

About Segra 

Segra is an agricultural life sciences company specializing in cannabis plant micropropagation. The company is developing industrial-scale cannabis micropropagation laboratories in Canada and California to produce disease-free, genetically verified plantlets for licensed producers globally. Segra has assembled a world-class team of specialists in the areas of plant tissue culture, agronomy, molecular genetics, regulatory compliance, and corporate finance. The Segra team includes Dr. Sma Zobayed, a world-renowned plant micropropagation specialist who has successfully micropropagated over 500 unique plant cultivars, including cannabis.

On behalf of the Board of Directors,
Todd McMurray, President/CEO
SEGRA INTERNATIONAL CORP.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Segra International Corp.

For further information: Kevin Mehr, Email: kevin.m@segra-intl.com

The post Segra Signs Agreement with Agripharm for Large-Scale Cannabis Plant Micropropagation Services appeared first on CannabisFN.

Canntab Brings Pharma Standards to Medical Cannabis

Written by Ryan Allway on

According to Arcview Market Research the North American cannabis industry is expected to grow more than three-fold from $6.57 billion in 2016 to $20.2 billion by 2021. The legalization  of adult-use cannabis by the government of Canada will open the door to a much wider market in Canada, where legalization is currently anticipated for the summer of 2018. There are signs that U.S. lawmakers are ready to further legitimize medical cannabis by potentially removing marijuana from the list of Schedule I Controlled Substances.

As with any rapidly expanding market, there have been many growing pains along the way. Canadian licensed producers have been plagued with recalls for contaminated products due to the lack of testing standards, while inaccurate labeling has hurt consumers’ trust in the regulated medical cannabis space. Many medical cannabis companies and doctors also struggle with dosing issues given the unique nature of cannabis and the lack of robust clinical trial data.

CannTab Therapeutics Inc. (CSE: PILL) aims to deal with these issues by making medical cannabis more reliable with its proprietary, patent-pending, extended-release tablets that offer a reliable and uniform dosage over several hours. By making medical cannabis more like traditional pharmaceuticals, these products should be more readily prescribed by doctors than the smoking of cannabis flower. Dr. Andrew Weil, director of integrative medicine at the University of Arizona College of Medicine states, “As a physician, I am frustrated that I cannot prescribe marijuana for patients who might benefit from it. At the very least I would like to be able to refer them to a safe, reliable, quality-controlled source.”

A Lack of Standards

Cannabis bioavailability is a significant issue facing the medical community. In a 2009 study, researchers found that cannabinoid bioavailability ranged from two to 56 percent for inhaled cannabis smoke and from four to 20 percent for orally consumed cannabis products. These wide ranges make it difficult for physicians to anticipate how cannabis will affect a patient, which makes them less likely to prescribe cannabis-based medications.

The reality is that cannabis affects different people in different ways due to its nature. For one, cannabis contains hundreds of cannabinoids that interact in ways that scientists are only starting to understand. The metabolism of cannabinoids also depends on an individual’s body type since it’s a fat-soluble and subject to first-pass liver metabolism. And finally, regular users may build up a tolerance and require higher dosing than casual or new users.

Many companies have started to develop cannabinoid delivery mechanisms designed to improve bioavailability, but it’s a challenging task that requires extensive research and development. In addition, many of these delivery mechanisms may be unfamiliar to patients that are accustomed to taking pharmaceutical drugs in pill form. The most promising companies are those that are closely adhering to pharmaceutical standards.

Canntab’s Unique Solutions

Canntab Therapeutics aims to develop advanced pharmaceutical-grade cannabis formulations. Using its in-house technology, the company delivers standardized medical cannabis extract from selective strains in a variety of extended-release/sustained release pharmaceutical dosages for therapeutic use. As the company likes to say, it puts the “medical” into “medical cannabis” by bringing pharmaceutical standards to the industry.

The company’s proprietary, patent-pending Canntab XR Tablets provide an extended release and uniform dosing of cannabis over an extended number of hours. Doctors or patients can access a wide range of THC/CBD variations to effectively manage any ailment, while taking advantage of the discreet tablet format that easily fits into any patient’s lifestyle. These tablets are also highly reliable and made to pharmaceutical-grade standards.

In late-2017, the company signed a licensing deal with Emblem Corp. (CSE: EMC), a Canadian licensed producer of medical cannabis, to market and develop five products in Canada, and closed a joint venture deal with Queensland Bauxite to make its products available in Australia and Asia. Recently, Health Canada approved R&D activities for Canntab’s oral sustained release formulations of cannabinoids, which paves the way for these new products.

“We are thrilled that Health Canada has approved the research and development phase of our partnership with Canntab,” said Emblem President and CEO Nick Dean in the press release announcing the approval. “The introduction of Canntab’s sustained release formulation presents a significant growth opportunity for Emblem that is expected to begin in 2019.”

In addition to that licensing deal, the company announced a joint venture with Queensland Bauxite (ASX: QBL) to develop and market its patented tablets. The new venture will compete with MMJ Phytotech (ASX: MMJ), which is the only company that’s currently importing a cannabis-containing pill in partnership with the Swiss drugmaker, Satipharm. Queensland Bauxite is confident that the standardized dosing will convince doctors and regulators to support the product as a way to prescribe measurable doses of cannabis.

Management is also working to close a deal to co-locate with FV Pharma to produce and distribute its products in Canada and around the world.

Looking Ahead

CannTab Therapeutics Inc. (CSE: PILL) represents a compelling investment opportunity within the burgeoning cannabis industry. By addressing key issues with bioavailability and dosing, the company’s products should appeal to traditional doctors and patients looking for reliable solutions to meet their medical needs. Recreational users will be able to benefit from a consistent experience as well.

For more information, visit the Company’s Website at: Canntab Therapeutics Inc.

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Canntab Brings Pharma Standards to Medical Cannabis appeared first on CannabisFN.

Pivot Signs Exclusive Manufacturing Agreement with Bio V Pharma Inc.

Written by Ryan Allway on

Bio-Cannabis Product Pipeline Ready To Be Commercialized In Canada

VANCOUVER, May 30, 2018 /CNW/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to announce that it has signed an exclusive Contract Manufacturing Agreement (the “Agreement”) with Bio V Pharma Inc. (“BioV”) to manufacture, label, package and supply Pivot’s bio-cannabis product pipeline. BioV is a Quebec-based full-service manufacturer of pharmaceutical and nutraceutical products including vitamins, botanical products, food and veterinary supplements and specializes in capsules, tablets, liquids and semi-solids delivered in a variety of packaging formats.

The BioV management team has over 40 years of experience in product development and manufacturing and will produce Pivot’s entire bio-cannabis suite of products including BiPhasix™ topical creams and lotions, Thrudermic™ transdermal gels and lotions, Solmic™ 1% CBD oral solution, and “RTIC™” Ready-to-Infuse-Cannabis Powder presented in capsules, single-use sachets and bulk packages.

Pivot has engaged Cannabis Compliance Inc. (“CCI”) to apply to Health Canada for a Dealer’s License (“Dealer’s License”) under the Controlled Drugs and Substances Act (“CDSA”) and the Narcotic Control Regulations.  Pivot’s Dealer’s License will be attached to the BioV facility in Dollard-des-Ormeaux, Quebec, enabling the Company to perform research and development, process natural health products, store cannabis derivatives, as well as import and export cannabis oils, concentrates and approved derivatives. In addition, a DL will also allow the Company to formulate cannabis products in various dosage forms, strengths or package sizes to support future market research and product innovation opportunities.

Dr. Patrick Frankham, Pivot’s CEO, stated “We are excited to have chosen Bio V Pharma as our Canadian manufacturing partner at this important time in Pivot’s history. Consumers and regulators will demand high-quality products that are manufactured in cGMP facilities by a knowledgeable and experienced team. BioV has a track record of supplying retail pharmacy chains, including Shoppers Drug Mart and London Drugs, with products meeting the highest quality standards. We continue to execute on our business plan to monetize our platform technologies by commercializing our suite of premium, science-based cannabis products in key markets.”

Pivot is currently in discussions with several Canadian Licensed Producers to secure supply of pharmaceutical-grade cannabis oils and isolates and expects to finalize a Supply Agreement shortly. Upon receipt of a Dealer’s License from Health Canada, Pivot will be ready to market its differentiated portfolio of products to consumers in Canada and the EU.  The Company remains on target to generate revenue in Q4 2018 from its operations in California, Canada and select EU countries.

About Bio V Pharma Inc.

Bio V Pharma is a Canadian based full-service manufacturer of pharmaceuticals and nutraceutical products including vitamins, botanical products, and food supplements. With over 40 years of experience in product development and manufacturing, Bio V currently services North America, Europe & the Middle East and is internationally recognized for quality & service, meeting the most stringent compliance and documentation requirements. For more information please visit www.biov.ca

About Cannabis Compliance Inc.

Cannabis Compliance Inc. offers risk mitigation, due diligence and regulatory compliance for commercial cannabis producers and resellers around the world. We focus in the global market, and provide our clients with trusted and comprehensive solutions. CCI has extensive expertise in regulatory compliance, cultivation/horticulture, security designs/tender, facility designs/build-outs, quality assurance programs, import & export, staff recruitment and financial planning. CCI exists to empower the future leaders in the global cannabis industry. For more information please visit www.cannabiscomplianceinc.com

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, Bio V Pharma Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, statements with respect to internal expectations, including with respect to the Dealer’s License, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Cision View original content:http://www.prnewswire.com/news-releases/pivot-signs-exclusive-manufacturing-agreement-with-bio-v-pharma-inc-300656208.html

SOURCE Pivot Pharmaceuticals Inc.

View original content: http://www.newswire.ca/en/releases/archive/May2018/30/c5239.html

Pivot Pharmaceuticals Inc., Patrick Frankham, PhD, MBA, Chief Executive Officer, Email: Info@PivotPharma.com; Virtus Advisory Group, Investor Relations, Email: Pivot@virtusadvisory.com, Phone: 416-644-5081Copyright CNW Group 2018

 

Source: Canada Newswire (May 30, 2018 – 3:05 AM EDT)

The post Pivot Signs Exclusive Manufacturing Agreement with Bio V Pharma Inc. appeared first on CannabisFN.

SpeakEasy Signs a MOU to Bring Premium Cannabis to Germany and the European Union with HerbaMedica GmbH

Written by Ryan Allway on

VANCOUVER, May 29, 2018 /CNW/ – Speakeasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “SpeakEasy”) a late stage ACMPR applicant is pleased to announce it has signed a memorandum of understanding with HerbaMedica GmbH to export premium cannabis to Germany and the EU markets.

HerbaMedica will buy/distribute a fixed amount of products from SpeakEasy and SpeakEasy will provide this amount every year, initially this obligation shall last for three years after the binding conclusion of the Venture. The before mentioned amount shall be fixed between the parties once the German authorities have granted the license, companies will engage in signing a definitive agreement, with further in-depth details being provided, independent from the allowed amounts according to that license. In the before mentioned period of initially three years Partner will only distribute or sell Products to or in Germany and the EU via HerbaMedica. “By having HerbaMedica distribute our products throughout the EU, we gain access to a significant amount of possible clientele. Currently there are only 7 approved Cannabis importers to Germany, Speakeasy is excited to be a applicant for this opportunity to join this group of selected few.” Stated Marc Geen of CEO Speakeasy.

HerbaMedica plans to give SpeakEasy access to the German and EU market (to the extent that the latter is included in the access to the German market) with applying and paying for their inspection. The inspection will consist of two stages. Initially a specialised Consulting Company regarding the EU GMP (Good Manufacturing Practice) and EU GACP (Good Agricultural Cultivation Practice) will inspect the sites and advise on necessary improvements / changes to receive the EU license. Thereafter the sites will be inspected by the competent German authorities. The external costs for the inspection will be borne by HerbaMedica, internal preparation / improvement costs of SpeakEasy will remain with the SpeakEasy.

“SpeakEasy is a great fit for Herba Medica because of the extensive knowledge Marc and his team bring to the table in all facets of the cannabis industry. Both our companies specialties are very complimentary to each other.” – Stated HerbaMedica CEO David Hohne

About HerbaMedica:

HerbaMedica is late stage applicant for importing cannabis into Germany. It was founded in Summer 2017 to become a importer of premium cannabis flower and cannabis based products to Germany and the European Union. Currently there are seven importers which are all importing from the same sources into the German market.

ON BEHALF OF SPEAKEASY CANNABIS CLUB LTD.

(signed) “Marc Geen“

Chief Executive Officer

Not for distribution to United States wire services or dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Statements about the Target’s future facility expansion plans or ACMPR license application are all forward-looking information.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE SpeakEasy Cannabis Club Ltd.

View original content: http://www.newswire.ca/en/releases/archive/May2018/29/c5518.html

Speakeasy Cannabis Club Ltd., www.speakeasygrowers.com, Telephone: 604-283-1722Copyright CNW Group 2018

 

Source: Canada Newswire (May 29, 2018 – 4:34 PM EDT)

The post SpeakEasy Signs a MOU to Bring Premium Cannabis to Germany and the European Union with HerbaMedica GmbH appeared first on CannabisFN.

City View Green Engages CFN Media to Build New Investor Audience

Written by Ryan Allway on May 29, 2018

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that City View Green (CVG) has engaged CFN Media to conduct an 6-month investor and market visibility program to begin on May 30, 2018.

“City View Green, a new LP applicant within reach of its cultivation through Health Canada, has an exclusive 20-year lease on a 40,000 sq. ft. facility located in Ontario with estimated production of five kilograms per year once upgrades are completed,” said Frank Lane, President of CFN Media. “CVG will focus on high quality extraction for the Canadian and international markets. The company will also grow for the recreational market in Canada once legalized”.

“At City View Green we are excited by the opportunity that we feel the cannabis industry represents and are looking forward to working with CFN Media. In the near future we will have more to report as we plan the retrofit of our Brantford facility as well as exciting new developments ” said City View Green President David Roff.

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to City View Green while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading agency and financial media network dedicated to the worldwide cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Private and public marijuana companies in the US and Canada rely on CFN Media to succeed in the capital markets.

About City View Green

CVG is targeting entry into the Canadian Medical and Recreational market in 2018 as a high quality, large-scale cannabis producer. CVG is an ACMPR applicant strategically located in Branford, Ontario, which is in close proximity to one of Canada’s largest cities – Toronto, Ontario. 

Upon issuance of the license, CVG proposes to operate out of a 40,000 ft² facility which it has leased and intends to grow pharmaceutical grade cannabis to be sold in the current medicinal market and the upcoming recreational market, upon legalization. CVG is currently advancing the design and retrofit of the Brantford facility through experienced contractors with extensive knowledge of building construction in the pharmaceutical and medical marijuana industries.

CVG intends to incorporate innovative growing strategies which may be based on technological advancements in LED lighting, advanced HVAC and dehumidification technology, and automation. This progressive growing technology is expected to improve the quality, safety, output and consistency of its cannabis production. 

CVG’s management believes that its strategic location in Brantford, Ontario should enable it to be able to draw on the best talent available in the market which is in close proximity to several agricultural learning centres, colleges and universities. FDi, a division of Financial Times Limited, ranked the City of Brantford at the top spot as the most business-friendly city in the micro city category in the 2017/2018 FDi report. 

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post City View Green Engages CFN Media to Build New Investor Audience appeared first on CannabisFN.

RavenQuest Reports Progress Across All ‘Four Pillars’

Written by Ryan Allway on

Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis later this year. While there are many companies active in the space, there are few that are as unique and diversified as RavenQuest BioMed Inc. (CSE: RQB) (OTCQB: RVVQF), which has taken a ‘four pillar’ approach to the cannabis industry to build long-term shareholder value.

RavenQuest BioMed recently released a corporate update reporting progress across all four of its pillars, including investments, indigenous peoples outreach, consulting services, and research and development. Investors may want to take note of these developments and the company’s many near-term catalysts coming up just as adult-use cannabis becomes legal.

Ramping Up Operations

RavenQuest BioMed invested in two new projects at the memorandum of understanding phase, including a 250,000 sq. ft. joint venture with Fort McMurray #468 First Nation and the acquisition of Western AgriPharma Limited, a late-stage ACMPR applicant with 125,000 sq. ft. of growing space. Management anticipates that these two investments will increase its production footprint from 11,000 kilograms to over 50,000 kilograms of dried cannabis per year.

At the same time, the company’s licensed (cultivation) Bloomera facility in Toronto completed the first of two harvests required by Health Canada for license to sell and dispense. The facility successfully passed all chemistry and microbiological testing on the first grow cycle and management expects a license to sell and dispense by July. Additionally, the company’s Alberta Green Biotech facility is fully funded and expected to be licensed to cultivate by July.

The company also recently signed a new lease in downtown Edmonton where it plans to open its flagship retail recreational cannabis store. The space is strategically located within Edmonton’s downtown nightlife, concert halls, conference center, public transport, and popular “ICE District” that’s home to NHL hockey and a densely populated residential area.

Research & Partnerships

RavenQuest BioMed’s Head of Government and Indigenous Relations, Bill Robinson, recently hosted the first national conference call for the Indigenous Peoples’ Cannabis Association (IPCA). Over the past several months, IPCA’s membership has continued to rapidly grow along with interest from indigenous communities looking to participate in the cannabis industry. These relationships could be extremely valuable to the company over the long run.

CEO George Robinson will also be working to expand the company’s presence by speaking at several upcoming cannabis industry events, including:

  • Arcview International Investor Forum: April 30-May 2 Vancouver, BC
  • Institutional Capital & Cannabis Conference: May 21-22 Los Angeles, CA
  • International Cannabis Business Conference: June 24-25 Vancouver, BC
  • The Money Show (Cannabis Investing Symposium): August 23-25, San Francisco, CA
  • The Money Show (Cannabis Investing Symposium): Sept 14-15, Toronto, ON
  • Institute of Public Administration of Canada (Pracademic policy workshop): Aug. 22, Quebec City, PQ

In addition to building strategic relationships, the company received a $480,000 grant from the Natural Sciences & Engineering Research Council (NSERC) along with its research partner, McGill University. These funds will be combined with the company’s cash and in-kind contributions to yield a total of $1.2 million over three years. These funds will be aimed at recognition, stabilization, and yield maximization of the cannabis plant.

Looking Ahead

RavenQuest BioMed Inc. (CSE: RQB) (OTCQB: RVVQF) has made tremendous progress in advancing its four pillars approach to the cannabis industry. The investment division has continued to expand its portfolio; the indigenous peoples outreach has seen strong early traction; the services division produced over $600,000 in revenue last quarter; and, the R&D branch successfully secured a NSERC grant to improve cannabis production.

For more information, visit the company’s website or download their investor presentation.

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post RavenQuest Reports Progress Across All ‘Four Pillars’ appeared first on CannabisFN.

CROP Infrastructure Announces the Appointment of Mr. David Weinkauf to the Executive Advisory Board

Written by Ryan Allway on

VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) — CROP Infrastructure Corp. (CSE:CROP) (OTCMKTS:CRXPF) (“CROP” or the “Company”) announces the appointment of Mr. David Weinkauf to the Executive Advisory Board of CROP Infrastructure Corporation.

CROP Infrastructure CEO Michael Yorke stated, “We are very pleased to have David join the CROP advisory board at this active and exciting time for the Company and the Cannabis industry. David’s extensive real-estate development experience will help guide CROP as we aggressively pursue the expansion of our operations portfolio globally.”

Throughout Mr. Weinkauf’s real-estate career and was involved in approximately $3 Billion in transactions while developing around 3,000 acres of real estate. Mr. Weinkauf was recognized as Calgary’s top 40 under 40 in 2004 and was nominated for Canada’s top 40 under 40 in 2006 after graduating from the University of Calgary in 1993, with a Bachelor of Commerce Degree focused on Marketing and Finance.

David’s volunteer work has been extensive including sitting as a member of the board of directors of Children’s wish foundation of Alberta and the NWT and sitting as advisor to the president of the advisory committee to Calgary Economic Development.

Mr. David Weinkauf commented: “As an entrepreneur at heart with my first successful incorporated business at age 21, my life’s work has been growing small firms into bigger companies, working to promote good people and good products while having fun and success along the way.  I look forward to providing my knowledge of real estate and my background in startups to CROP infrastructure Corp’s team and their portfolio of greenhouse infrastructure and agricultural assets.”

David’s full bio is available at https://cropcorp.com/about-us/

Furthermore, the Company would like to announce that Mr. Alex Horsley has stepped down from his position on the board of directors for CROP Infrastructure.  The Company thanks Mr. Horsley for his time as a director and wishes him all the best in his future endeavors.

About CROP Infrastructure Corp.
Crop Infrastructure is engaged in the business of investing, constructing, owning and leasing mega-greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes licensed greenhouse facilities in California and Washington State.

Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Phone: (604) 484-4206

Disclaimer for Forward-Looking Information
Certain statements in this press release related to the Offering, the securities issuable thereunder and the Transaction are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the proceeds to be raised pursuant to the Offering, availability of exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 and the expected uses of the funds advanced under the Loan by Humboldt. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Company’s ability to complete the Offering and the uses of the funds advanced under the Loan by Humboldt, including the risk that the Offering may not be completed as expected or at all, that the proceeds of the Offering may be used other than as set out in this news release, that the funds advanced under the Loan by Humboldt may be used other than as set out in this news release and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Source: GlobeNewswire (May 29, 2018 – 9:00 AM EDT)

The post CROP Infrastructure Announces the Appointment of Mr. David Weinkauf to the Executive Advisory Board appeared first on CannabisFN.

BLOCKStrain Welcomes WeedMD to its Platform

Written by Ryan Allway on

VANCOUVER, May 29, 2018 /CNW/ – BLOCKSTRAIN TECHNOLOGY CORP. (TSXV: DNAX) the “Company“) is pleased to a welcome WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) to its platform. WeedMD, which recently announced a merger with Hiku Brands Company Ltd. (CSE: HIKU), is the first Licensed Producer (LP) under Health Canada’s Access to Cannabis for Medical Purposes Regulations to utilize BLOCKStrain’s proprietary platform, making it one of the first federally Licensed Producers of medical cannabis to integrate blockchain technology into its ecosystem.

BLOCKStrain Technology Corp. (CNW Group/BLOCKStrain Technology Corp.)

BLOCKStrain’s platform will allow for the expansion of WeedMD’s library of world-class cannabis genetics while building customers’ trust. BLOCKStrain, which began trading publicly last week on the TSX Venture Exchange, delivers a secure and immutable blockchain platform to establish global certainty for cannabis strains and their ownership.

“Our talented product development team has had the distinct pleasure of working with the amazingly knowledgeable cultivation and production management team at WeedMD to better shape our core product suite, and to provide digital solutions which aim to reduce inefficiencies and administrative pain points,” commented BLOCKStrain CEO Robert Galarza. “Our mission is to provide WeedMD with a secure record for their vast array of genetics, while also assisting in streamlining certain internal functions given our technology platform and knowledge.”

BLOCKStrain’s team has worked hand in hand with the team at WeedMD to create a digital process for automating the “Production Batch Record” summary which is part of the documentation requirements set by the federal government. Currently the mandated process, although necessary for consumer safety and quality assurance, is burdensome, time intensive and requires far too much manual paperwork.

“The current process has many flaws, including the inability to easily reference and manage the collected data, and to analyze, share or derive insights from the data collected,” stated BLOCKStrain co-founder and Chief Technology Officer Tommy Stephenson. “This makes it virtually impossible to use the data when and where it is truly needed in the industry.”

BLOCKStrain tackled this issue by developing a new solution that is rapidly accessible with mobile devices and tablets and removes many redundancies currently in the current system.
“Our application mirrors what a producer is manually doing in order to provide a massive amount of value in time saved as well as cost reductions, while also providing quick access to data and insights that help optimize operations,” said Mr. Stephenson.

BLOCKStrain has also developed a “Wholesale Record” summary to assist in the WeedMD’s wholesale genetics business, thus providing WeedMD with the ability to manage and share the history of a clone, as well as the data collected during its grow cycle.

“We believe that this internal level of insight, which is collected throughout the growing cycle, is unparalleled in the industry and will be incredibly valuable to the LP customer base currently purchasing clones from WeedMD’s top-quality inventory of genetics,” stated Mr. Galarza.

“Unique and differentiated strains and product offerings have always been, and will remain, a cornerstone of WeedMD’s business model”, said Keith Merker, Chief Financial Officer of WeedMD. “Validating and protecting that intellectual property through BLOCKStrain’s platform will prove invaluable as we scale operations and broaden our distribution throughout the country as well as internationally.”

The digital solutions provided by BLOCKStrain are expected to be instrumental in providing WeedMD’s cultivation team with tools to rapidly search their records in real time instead of sifting through large volumes of paperwork in the company’s files. Furthermore, the digital archival system of BLOCKStrain is expected to prevent forms from being damaged, lost or tampered with and to make it easy to share with colleagues and regulatory bodies. This powerful data can also be accessible for analytics, reporting and measurement and is the only solution on the market that provides this level of service to one of Canada’s leading cultivators.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distibutor of medical cannabis and oils under the ACMPR. The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. WeedMD is focused on providing medical cannabis to the seniors’ markets in Canada through its proprietary seniors’ care program. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

About BLOCKStrain Technology Corp.

BLOCKStrain Technology Corp. (TSX-V: DNAX.V) has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry. Strain protection and genetic identification are major issues for growers and breeders, and this new technology allows them to identify and secure rights to their valuable intellectual property. The BLOCKStrain platform also streamlines the administrative process of genetic and mandatory quality-control testing for legal cannabis, cutting the administrative time and expense in half.

BLOCKStrain’s proprietary, immutable, cryptographically-secure blockchain-technology establishes a global ‘single source of truth’ for cannabis strains, their ownership, potency and chemical makeup. In an industry where a popular strain can be worth millions of dollars, it is crucial to the industry’s future to quantify genetics, potency and equivalencies between cannabis products. BLOCKStrain aims to deliver needed transparency to growers, retailers, regulators, and consumers who have struggled to find realistic solutions to these logistical challenges. The blockchain technology implemented by BLOCKStrain is ideally suited to solve these problems by implementing an immutable and non-corruptible record of transactions.

ON BEHALF OF THE BOARD OF DIRECTORS

“Robert Galarza”

Robert Galarza
Chief Executive Officer and Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to the expected benefits of, and impact on, WeedMD’s business as a result of the use of BLOCKStrain’s technology; and the expected security and other benefits of BLOCKStrain’s technology generally. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: BLOCKStrain’s platform may not operate as expected; WeedMD may not derive the expected benefits from use of the BLOCKStrain platform; legislative changes may occur that negatively impact BLOCKStrain’s business; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE BLOCKStrain Technology Corp.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2018/29/c3941.html

Contact Paula Arab by phone at (403) 889-9128 or by email at paula.arab@blockstrain.ioCopyright CNW Group 2018

 

Source: Canada Newswire (May 29, 2018 – 8:00 AM EDT)

The post BLOCKStrain Welcomes WeedMD to its Platform appeared first on CannabisFN.

CFN Exclusive Interview: MedMen Becomes Canada’s Next Billion Dollar Cannabis Listing

Written by Ryan Allway on

MedMen Enterprises (CSE: MMEN), a California-based cannabis retailer that’s well-known for its sleek Apple Store-like retail locations across the United States, has finalized its reverse takeover and today is becoming one of the largest publicly-traded cannabis firms in the world.

The company is listing on the Canadian Securities Exchange, or CSE, following its reverse takeover of Ladera Ventures Corp. It is one of the first U.S. marijuana companies to list on the CSE. U.S. marijuana companies are currently barred from the TSX, Nasdaq and NYSE. The exposure on the CSE gives MedMen access to retail investors on a global scale and could fuel its already robust growth pattern.

Unique Experience

MedMen operates 12 licensed retail outlets in California, New York, and Nevada, including a 2,000 sq. ft. flagship store on New York City’s Fifth Avenue and another location on Santa Monica Boulevard in West Hollywood. In addition to dispensary operations, the company owns a 45,000 sq. ft. state of the art cultivation facility in Nevada and has broken ground on another in California to expand its cultivation operations.

CFN Media recently interviewed MedMen CEO Adam Bierman. Mr. Bierman discusses the reasons behind and the benefits of going public, along with the company’s potential going forward.

 

MedMen has taken the cannabis buying experience a long way from back-alley transactions just a few years ago. Its dispensaries are more akin to Apple Stores in terms of their bright and open architecture, as well as knowledgeable staff members in memorable red T-shirts. Management’s goal is to destigmatize cannabis and make mainstream adults feel comfortable purchasing product and carrying it out the door in the open.

“MedMen’s vision is simple but revolutionary: cannabis as a consumer product,” said MedMen Co-founder and CEO Adam Bierman. “For the better part of a decade we have been singularly focused on that vision – creating the systems and infrastructure that raise the bar on product quality and safety and providing a retail shopping experience that is second to none. By transitioning to a publicly-traded company, MedMen gives public investors a ground-floor opportunity to participate in the enormous and untapped potential of the fastest growing industry in the United States.”

MedMen Fifth Avenue

Growing Footprint

MedMen is primarily focused on acquiring top real estate to ensure that it will remain compliant with laws prohibiting locations close to schools, churches, or parks, as well as increase the reputability of its brand as a top-shelf option in major metro markets. The goal is to expand into these major markets as quickly as possible to build up a competitive edge against competitors that have been rolling out slowly in states like Colorado.

At the same time, the company recently partnered with Cronos Group Inc. (NASDAQ: CRON) to create a joint venture that will develop products and open MedMen-branded locations across Canada when recreational cannabis is legalized this summer. The move should help diversify operations and significantly increase revenue as it competes with the primarily mail-order industry that has built up in Canada around licensed producers.

Compelling Investment

With a pre-money valuation of $1.65 billion, MedMen could immediately become one of Canada’s ten largest cannabis companies and the most valuable U.S.-based cannabis company by market capitalization. The majority of the cannabis unicorns, or those companies with $1+ billion market capitalizations, are licensed producers of medical cannabis in Canada, including Canopy Growth Corp. (TSX: WEED) and Aurora Cannabis Inc. (TSX: ACB).

Investors may want to take a closer look at the stock given its unique reach into diverse U.S. markets and its focus on building a defensible national brand. At the same time, the company efforts to expand into Canada could unlock incremental value for shareholders following recreational legalization later this year.

MedMen Enterprises (CSE: MMEN) represents a compelling opportunity to invest in the cannabis industry. With its growing U.S. footprint, the company offers one of the only truly diversified plays on the U.S. cannabis industry. Meanwhile, its listing on the CSE ensures that investors across North America can easily acquire a piece of the company.

The post CFN Exclusive Interview: MedMen Becomes Canada’s Next Billion Dollar Cannabis Listing appeared first on CannabisFN.

The Green Organic Dutchman to Exclusively License Fast-Acting Stillwater Foods’ RIPPLE SC (Soluble Cannabinoids) and Other Proprietary Beverage and Food Technologies

Written by Ryan Allway on

TORONTO, May 29, 2018 (GLOBE NEWSWIRE) — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) is pleased to announce  that the Company has entered into an exclusive agreement with Stillwater Brands to license RIPPLE SC (Soluble Cannabinoids) ingredient technology, and other proprietary beverage and food technologies and formulations related to cannabinoid-infused consumer packaged goods including micro-dose and full-dose tea sticks within Canada and certain international jurisdictions outside of the USA.

RIPPLE SC is a proprietary, patent-pending suite of low-calorie, fast-acting, water-soluble ingredient products that allows consumers or commercial manufacturers to simply and easily infuse cannabinoids into beverage and food products. RIPPLE SC is formulated to absorb into the bloodstream within fifteen minutes and last for up to four hours, allowing RIPPLE SC-based edibles to offer a uniquely consistent and controlled experience that consumers can trust. Further, while cannabis is by nature fat soluble, edibles utilizing RIPPLE SC’s unique technology require no added fat to carry cannabinoids or sugar to mask cannabinoids’ natural bitterness. As a result, RIPPLE SC enables healthier, better-tasting edibles with no additional sugar, fat, or artificial flavorings.

RIPPLE SC has already proven its value in Colorado, where its consumer variant (marketed as Ripple Dissolvables) is among the fastest-growing products in the edibles category. RIPPLE SC technology also powers other high-end consumer brands such as Stillwater Tea and Whitewater Tea.

TGOD intends to offer Ripple Dissolvables and other Stillwater Brands products and formulations in international markets outside of the USA where regulations allow, as well as in the Canadian market once permitted by the Canadian regulatory regime. Further, TGOD intends to aggressively work on other novel formulations in the beverage, functional foods and dietary supplements areas which will contemplate using RIPPLE SC as the base water-soluble cannabinoid input.

“We believe that soluble cannabinoids and the consumer benefits they enable represent the future of functional foods,” said Justin Singer, CEO of Stillwater Brands. “TGOD’s emphasis on organic, high-quality consumer products makes the Company an ideal partner to carry our vision into the Canadian and international markets.”

“We are excited to have the opportunity to provide a platform to introduce Stillwater’s advanced technologies and formulations worldwide using TGOD’s premium organic ingredients,” said Rob Anderson, Co-Chairman and CEO of TGOD. “This technology will allow TGOD to provide patients and customers around the globe with novel and effective dose-controlled delivery systems that are safer, more standardized, and more discreet than most current cannabinoid delivery systems.”

On Behalf of the Board of Directors,

The Green Organic Dutchman Holdings Ltd.
Robert Anderson
Chief Executive Officer and Co-Chairman

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Green Organic Dutchman Holdings Ltd. is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 116,000 kg and is building 970,000 sq. ft. of cultivation facilities in Ontario and Quebec.

The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX:ACB) whereby Aurora has invested approximately $78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately $290 million dollars and has over 5,000 shareholders.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

CONTACT INFORMATION

Investor Relations
Email: invest@tgod.ca
Phone: 1 (416) 900-7621

www.tgod.ca

ABOUT STILLWATER FOODS
Stillwater Foods is a functional foods company specializing in the processing, manufacturing and distribution of soluble cannabinoid-infused consumer packaged goods and ingredients. The company’s business-to-consumer arm (Stillwater Brands) produces some of Colorado’s leading THC- and CBD-infused edibles brands, including Ripple dissolvable cannabinoids, Stillwater Tea, Whitewater Tea and Clockwork Coffee. Its business-to-business arm, Stillwater Ingredients, manufactures RIPPLE SC (Soluble Cannabinoids), a suite of standardized, clean-label, shelf-stable formulations of isolated cannabinoids that mix easily into wet or dry food systems, withstanding standard commercial food processes and temperatures. RIPPLE SC allows manufacturers to simply and easily introduce fast-acting, water-soluble cannabinoids into any food environment using standard commercial kitchen or food production equipment with no noticeable impact on flavor, consistency, texture, or appearance — no specialized knowledge or processing required. Backed by service, supported by execution and designed for scale.

STILLWATER FOODS CONTACT INFORMATION

Email: stillwater@wearebpr.com
www.stillwater.life

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the future legalization of recreational cannabis and cannabis-infused products in Canada, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

Primary Logo

The post The Green Organic Dutchman to Exclusively License Fast-Acting Stillwater Foods’ RIPPLE SC (Soluble Cannabinoids) and Other Proprietary Beverage and Food Technologies appeared first on CannabisFN.

Emerald Health Therapeutics Reports 1st Quarter 2018 Financial Results and Provides Corporate Update

Written by Ryan Allway on

Commences commercial production at its Pure Sunfarms Delta 3 joint venture greenhouse operation

VICTORIA, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the fiscal quarter ended March 31, 2018. They are available for viewing on www.sedar.com or on the Company’s website. All figures are expressed in Canadian dollars unless otherwise stated.

“Emerald has been very productive year-to-date in executing on three key strategic pillars: production scaling, product innovation, and branding,” said Chris Wagner, CEO of Emerald Health Therapeutics. “We received our cultivation license for our Pure Sunfarms joint venture, completed our first harvest and submitted an amendment to Health Canada for Pure Sunfarms’ sales license, and started commercial production. Emerald also established a supply agreement with Pure Sunfarms and acquired a licensed indoor production facility in Quebec to allow us to strongly serve consumers in Canada’s second largest province as well as add to our capabilities to serve the eastern Canadian market. We are taking progressive steps to advance intellectual property and product development. We are aggressively building our sales and marketing team, retained DDB Canada, a well-respected advertising agency, to help us build out our branding strategy. We also created a unique branding opportunity for Emerald in important, complementary sales channels.”

Selected Quarterly Financial Information

The financial information in the following tables summarize selected financial information for the Company for the last eight quarters which was derived from annual financial statements prepared in accordance with IFRS or interim financial statements prepared in accordance with IFRS applicable to the preparation of interim financial statements, IAS 34, Interim Financial Reporting:

2018
 2017
March 31
($)		 December 31
($)		 September 30
($)		 June 30
($)
Revenue 373,218 279,362 211,316 245,708
Share-based payments 1,954,047 1,979,553 271,968 369,788
Interest revenue 250,064 43,024 60,997 57,497
Share of loss from joint venture (301,793) (44,562) (278,016) –
Net Loss (5,045,420) (4,027,569) (1,939,371) (1,669,026)
Net Loss per share (basic and diluted) (0.04) (0.04) (0.02) (0.02)
2017 2016
  March 31
($)		 December 31
($)		 September 30
($)		 June 30
($)
Revenue 201,268 124,251 48,933 38,729
Share-based payments 201,186 137,113 467,878 37,618
Net Loss (1,205,858) (880,424) (1,009,841) (546,336)
Net Loss per share (basic and diluted) (0.02) (0.01) (0.02) (0.01)

BUSINESS UPDATE FOR AND SUBSEQUENT TO THE REPORTING PERIOD

Expansion Projects

The Company’s joint venture, Pure Sunfarms, continues to make great strides towards achieving its goal of large-scale, high-quality, low-cost cannabis production. On March 2, 2018, Pure Sunfarms received its cannabis cultivation licence from Health Canada. It completed its first harvests in May 2018 and has submitted to Health Canada its amendment package to attain its sales licence. Pure Sunfarms is now scaling commercial cultivation.

Pure Sunfarms continues to advance the development of the 1.1-million-square foot (25-acre) greenhouse facility located on a 50-acre parcel of land in Delta, British Columbia (“Delta 3”), with the entire 1.1-million square foot Delta 3 site expected to be in production in 2019. The facility will have 17 grow rooms and is designed to consistently deliver high-quality product and fulfill large-volume supply commitments.

Pure Sunfarms finalized a contract for the short-term rental of generating equipment to power supplemental lighting during the 2018/2019 winter months, while the installation of the approved additional 24MW by the local utility is in process.

Senior growing, financial, human resources and operational personnel, including the established team transferred from Village Farms, are in place.

Pure Sunfarms conservatively projects production of approximately 7,000 to 8,000 kilograms in 2018 and 46,000 to 52,000 kilograms in 2019.

The Company continues to focus on its second expansion project, a 500,000 square foot greenhouse in Metro Vancouver, British Columbia, but has recently experienced delays in obtaining required permitting for this project.

Supply Agreement

On April 30, 2018, the Company entered into a supply agreement with Pure Sunfarms whereby the Company will purchase 40% of Pure Sunfarms’ production in 2018 and 2019, approximately 21,000 to 24,000 kilograms using current projected production targets, at a pre-determined price per gram.

This agreement secures a significant source of cannabis for the Company as it endeavours to be an important supplier of high-quality cannabis in the anticipated legalized adult-use cannabis market.

Acquisitions

On May 2, 2018, the Company acquired 100% of the issued and outstanding shares of 8611165 Canada Inc. and its affiliate 9353-8460 Quebec Inc. (together “Agro-Biotech”) for consideration of $90 million, subject to adjustment, payable 50% in cash and 50% in shares. The Company paid $22.5 million in cash upon closing and $45 million was satisfied by the issuance of 9,911,894 common shares, of which 4,955,947 common shares will be held in escrow until May 1, 2019, pursuant to an escrow agreement. An additional $22.5 million in cash is payable on May 1, 2019.

Agro-Biotech is a Licenced Producer under Access to Cannabis for Medical Purposes Regulations. Located in Saint-Eustache, Quebec, Agro-Biotech’s assets include land and a 75,000 square foot indoor grow facility. The acquisition will increase the Company’s growing capacity and strengthen its ability to market its products in Quebec and Eastern Canada.

The indoor hydroponic growing facility, which has access to very low-cost energy and water, will be capable of high-yield production of Emerald’s unique cannabis strains, several of which are currently being grown in Agro-Biotech’s facility. Agro-Biotech has built out 20,000 square feet of this facility and expects to have a total of 50,000 square feet equipped for indoor cannabis cultivation by year end. Emerald intends to meet the requirements for an ACMPR sales licence for this facility before the end of August. This operation is estimated to have a have full production capacity exceeding 10,000 kg annually in 2019 and beyond.

On April 24, 2018, a statement of claim was served on Agro-Biotech and its former shareholders by a party with whom Agro-Biotech and its former shareholders had previously entered into a non-binding letter of intent with respect to a potential sale of Agro-Biotech. Management believes that the claim is without merit and intends to defend the claim to the fullest extent possible.

Sales and Marketing

In January, Emerald hired Mr. Paul Dillman as VP Sales & Marketing. With three decades of experience in global marketing, sales, and general management, he has held senior leadership positions at The Coca-Cola Company, AB InBev, Philip Morris, and Kraft Foods. Mr. Dillman is building Emerald’s sales and marketing team to prepare for the expected initiation of legal recreational cannabis use in Canada in the second half of 2018.

As part of this preparation, Emerald retained DDB Canada to assist with Emerald’s branding and marketing. The agency was named 2015 Digital Agency of the Year by Strategy magazine and was ranked #2 agency in Canada by the Gunn Report in 2015.

Emerald Health Naturals

Emerald Health Therapeutics entered into a 51:49 partnership with another Emerald Health group company, San Diego-based Emerald Health Bioceuticals Inc. (EHB), to create Emerald Health Naturals (EHN). EHN has secured exclusive Canadian rights to sell EHB’s award-winning non-cannabis health products that support the endocannabinoid system.

Market research shows that 6 of 10 cannabis users also purchase natural health products, which are primarily bought in natural health product, grocery, and pharmacy stores. While cannabis products are not expected to be distributed through these sales channels in the immediate future, EHN will have the opportunity to introduce this new non-cannabis product line into these stores and build brand recognition that may be broadly beneficial for Emerald’s cannabis product line.

DMG Blockchain Solutions Joint Venture

On January 28, 2018 the Company and DMG Blockchain signed a non-binding letter of intent to form a joint venture, to be named CannaChain Technologies, for the purpose of developing a blockchain solution to complement cannabis supply chain management and an e-commerce marketplace.

Namaste Technologies Collaboration

On January 30, 2018 the Company and Namaste signed a non-binding letter of intent whereby the Company and Namaste propose to enter into a definitive agreement to collaborate on strategic business opportunities worldwide and develop a fully integrated e-commerce platform to serve as a retail channel for the Company’s patients.

TSX Venture 50 Performer

The Company achieved the #1 ranking in the TSX Venture 50 for the clean technology & life science sector in 2017 and was recognized as a top performing company for the second consecutive year. The TSX Venture 50 is the TSX Venture Exchange’s annual ranking of Canada’s top 50 emerging publicly traded companies.

Capital Resources

Subsequent to year end, the Company raised additional gross proceeds of $71.7 million from private placement offerings and warrant exercises, bringing total gross proceeds raised since February 2017 from unit issuances and warrant exercises to $140.6 million.

The Company had approximately $74 million in cash and cash equivalents as at May 25, 2018.

As of May 25, 2018, the Company had 135.4 million common shares outstanding and 157.8 million common shares outstanding on a fully diluted basis, after giving effect to outstanding options, warrants, and restricted stock units.

Financial Reports

Full details of the financial reports and operating results for the first quarter of 2018 are described in the Company’s consolidated financial statements with accompanying notes and related Management’s Discussion and Analysis. These documents and additional information on Emerald are available on SEDAR at www.sedar.com.

About Emerald Health Therapeutics

Emerald Health Therapeutics (TSX-V:EMH) (OTCQX:EMHTF) (Frankfurt:TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald is preparing to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC and is now in commercial production. It owns Agro-Biotech, a Quebec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is highly experienced in life sciences, product development, large-scale agribusiness, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill Ray Lagace
CFO Investor Relations Manager
(800) 757 3536 Ext. #5 (800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. As a result, we cannot guarantee that any forward-looking statement will materialize and readers are cautioned not to place undue reliance on these forward looking statements. For more exhaustive information on these risks and uncertainties, the reader should refer to the risk factors described in the management’s discussion and analysis for the year ended December 31, 2017. The forward-looking statements contained in this press release represent our expectations as of the date hereof. We disclaim any intention and assume no obligation to update or revise any forward-looking statements. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

Primary Logo

 

Source: GlobeNewswire (May 29, 2018 – 8:00 AM EDT)

The post Emerald Health Therapeutics Reports 1st Quarter 2018 Financial Results and Provides Corporate Update appeared first on CannabisFN.

MedMen, Largest U.S. Cannabis Company, Begins Trading on the Canadian Securities Exchange May 29th Under Ticker Symbol “MMEN”

Written by Ryan Allway on

LOS ANGELES

Leading Cultivator, Producer and Retailer of State-Sanctioned Cannabis Now Accessible to Public Equity Investors

MedMen Enterprises Inc. will begin trading today on the Canadian Securities Exchange (“CSE”) under the ticker symbol “MMEN” at 11 a.m. EDT.

With more than 800 employees and 18 licensed facilities in California, Nevada and New York, MedMen is one of the fastest growing companies in the quickly evolving U.S. cannabis industry. The three states where MedMen currently operates account for about half of the addressable cannabis market in the U.S. State-sanctioned cannabis sales in the country are estimated at about US$7 billion annually and expected to reach US$75 billion by 2030, according to the Cowen Group.

“MedMen’s vision is simple but revolutionary: cannabis as a consumer product,” said MedMen Co-founder and CEO Adam Bierman. “For the better part of a decade we have been singularly focused on that vision – creating the systems and infrastructure that raise the bar on product quality and safety and providing a retail shopping experience that is second to none. By going public, MedMen gives investors a ground-floor opportunity to participate in the enormous and untapped potential of the fastest growing industry in the United States.”

The listing follows the successful completion of a reverse takeover of a Canadian public company by U.S.-based MM Enterprises USA, LLC. In connection with this reverse takeover and the listing on the CSE, the Company raised approximately CA$143 million, or US$110 million, through a private placement at an implied enterprise valuation of CA$2.14 billion, or US$1.65 billion. Executives of MM Enterprises USA, LLC were appointed as officers of the public company and the public company was renamed MedMen Enterprises Inc.

“We are making marijuana mainstream by making it okay for soccer moms and middle-aged professionals to use cannabis products,” said MedMen Co-founder and President Andrew Modlin, the creative force behind MedMen and the first cannabis professional to win the prestigious American Marketing Association’s Emerging Leaders Award. “People are using it for ailments, for wellness or to just relax or socialize with friends. Medical marijuana is legal in 29 states, adult use is now legal in nine. Medical use is legal in Canada and adult use is expected to be legal by year’s end. We are marching steadily toward a future where buying and using cannabis products will be just as normal as buying wine or beer.”

It is common for U.S.-based cannabis businesses to trade on the over-the-counter (“OTC”) market. In recent years, a growing number of American marijuana companies have sought a listing on the CSE, a more reputable, bona fide global exchange. Canada-based marijuana companies like the Cronos Group and Canopy Growth have listed on major U.S. exchanges recently, but U.S. marijuana companies are barred from listing on the NYSE or Nasdaq. The CSE gives American cannabis companies broader exposure to a global investor audience. Cassels Brock & Blackwell LLP acted as counsel to MedMen in connection with the financing and the listing on the CSE. MedMen engaged Cormark Securities Inc. and Canaccord Genuity Corp. to act as co-bookrunners on behalf of a syndicate of agents to complete the financing.

“Our listing on the CSE will give MedMen greater flexibility in accessing capital in the public equity markets to leverage our first-mover advantage and to build upon our track record of growth,” Bierman said. “At the same time, it will provide global investors an opportunity to invest in the preeminent cannabis company in the U.S. for the first time ever.”

One of the Most Recognized Brands in the Industry

Nine premium stores in the U.S. feature MedMen’s award-winning retail concept, including its flagship store on New York City’s Fifth Avenue, which opened last month. MedMen is licensed to operate a total of four stores in New York State, all of which are currently operational, and the Company plans to upgrade its three other New York stores to align with its distinctive retail brand. The Company also continues to explore and acquire prime real estate in upscale retail districts in strategic markets across North America. MedMen recently signed a joint venture agreement with Cronos Group to explore opening MedMen branded and managed stores in Canada once adult-use is legalized.

Industry Leading Cultivation and Production Facilities

MedMen operates scalable, highly-efficient cultivation facilities using the latest in agronomic technology and sustainable techniques, and its manufacturing facilities use standards comparable to those in the biotech and pharmaceutical industries. MedMen owns and operates two cultivation and production facilities, one in Nevada and the other in New York. The Company is currently developing additional large-scale cultivation and production operations in California and New York and a genetics facility in Nevada, while also expanding the cultivation area of its existing Nevada facility. Management intends to establish a strong foothold in these states as they offer high-growth potential due to their market depth, supply-demand dynamics and regulatory framework.

About MedMen

MedMen Enterprises is the preeminent cannabis company in the United States with multiple assets and operations in California, Nevada and New York, which combined account for nearly half of North America’s addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is one of the most well recognized cannabis brands in the world today. Headquartered in Los Angeles, MedMen Enterprises employs more than 800 people across the United States. The predecessor to MedMen Enterprises was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws. The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates. For more information, visit http://www.medmen.com or follow us on Facebook,Twitter or Instagram.

Concurrent with the public listing, the Company will launch its new investor relations website at investors.medmen.com.

A listing statement describing MedMen Enterprises and prepared in accordance with the policies of the CSE will be available on SEDAR at www.sedar.com.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of MedMen with respect to future business activities. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and include information regarding: (i) expectations regarding the size of the U.S. cannabis market (ii) the ability of the Company to successfully achieve its business objectives, (iii) plans for expansion of MedMen, and (iv) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect MedMen management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although MedMen believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the potential impact of the announcement of the going public transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; the inability to locate and acquire suitable companies, properties and assets necessary to execute on the Company’s business plans; and increasing costs of compliance with extensive government regulation. This forward-looking information may be affected by risks and uncertainties in the business of MedMen and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although MedMen has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. MedMen does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has in any way passed upon the merits of the proposed transactions described in this news release or has approved or disapproved of the contents of this news release.

MedMen Enterprises Inc.
Media Contact:
Daniel Yi
Senior Vice President of Corporate Communications
E-mail: daniel@medmen.com
or
Investor Relations Contact:
Stéphanie Van Hassel
Head of Investor Relations
E-mail: investors@medmen.com

Copyright Business Wire 2018

 

Source: Business Wire (May 29, 2018 – 3:01 AM EDT)

The post MedMen, Largest U.S. Cannabis Company, Begins Trading on the Canadian Securities Exchange May 29th Under Ticker Symbol “MMEN” appeared first on CannabisFN.

Exclusive: BLOCKStrain CEO Outlines Blockchain’s Potential Role in Cannabis

Written by Ryan Allway on May 28, 2018

Blockchain technology is disrupting the shipping and supply-chain industry by offering smart logistics that are cheap, efficient, transparent and protect intellectual property. BLOCKStrain is one such company, targeting its platform to more than 5,000 craft growers in Canada and upwards of 50,000 in California. Investors may want to take note ahead of recreational-use legalization across North America.

In an exclusive interview, CFN Media recently spoke with BLOCKStrain about its innovative platform and how it works.

BLOCKStrain Technology Corp (TSX-V: DNAX) recently went public on the TSX Venture exchange under the ticker symbol “DNAX” after many years of preparation and dedication toward building a premier software company serving the cannabis industry.

What is the Blockchain?

The term blockchain has been popularized by the rise of Bitcoin, but there’s a lot more to the technology than speculative currency. While cryptocurrencies rely on blockchains to verify transactions, the same technology can be applied to many different industries that require verified transactions. The shipping-and-supply-chain industry is perhaps the best example, but other verified transactions could include medical records, identity management, or even voting records.

At its core, a blockchain is a list of records where each record contains a cryptographic hash of the previous block, a timestamp, and transaction data. The difference between blockchain and traditional ledgers is that the blockchain is inherently resistant to modification (e.g. corruption) and it’s able to be read (e.g. verified) easily by the public. These attributes are highly desirable for many industries that want cheap, efficient, and transparent transactions.

Apply Blockchain to Cannabis

There are many companies that have launched cryptocurrencies within the cannabis industry. After all, the lack of access to traditional banking has left a void that digital currencies are well-positioned to fulfill. But, the potential for blockchain technology in the cannabis industry extends beyond consumer transactions to the supply chain, especially with more than 5,000 craft growers in Canada and more than 50,000 in California, alone.

Suppose that a craft grower partners with a licensed producer to market a new cannabis strain. The craft grower provides mother plants to the licensed producer, who agrees to mass produce and distribute the new strain and pay a licensing fee. Now, suppose that the licensed producer launches its own similar strain a few months later and suddenly stops paying licensing fees, claiming perhaps its strain is different and not the one from the initial mothering plant. How does the craft grower know that the licensed producer didn’t steal the proprietary strain? The blockchain where that identifying data is being held will unlock the answer, thus bringing a verifiable truth in the event of future disputes.

BLOCKStrain (TSX-V: DNAX) was created to address these issues by harnessing the benefits of blockchain technology. With an open and agnostic platform, the company’s technology utilizes the benefits of blockchain and enables growers to protect and license their products and see the visibility of supply chain logistics in real-time, without having to worry about larger players stealing their genetics or failing to pay them licensing fees that they’re owed.

How It Works

BLOCKStrain began by partnering with licensed testing facilities, streamlining the lab process and reducing administrative red tape. For every batch of product that is processed through these facilities, a blockchain transaction is created, thus becoming a unique identifier that is used as the product passes throughout the supply chain, and every partner that interacts with this identifier along the way can be sure that it has received the correct product. The process also reduces the overhead associated with traditional testing, which involves a lot of paperwork.

Craft growers know when the product has been sold and if they are due a licensing fee, while licensed producers can reassure their customers that they are receiving the correct product and that it has been tested by a licensed facility and is safe for consumption. Regulators can also just as efficiently verify that products have been tested before they’re sent to market, using the same blockchain record, thus reducing the headaches of paperwork or non-streamlined electronic records.

Looking Ahead

BLOCKStrain Technology Corp (TSX-V: DNAX) represents a compelling opportunity within the rapidly growing cannabis industry. With a platform that appeals to craft growers, licensed producers, consumers, and regulators, the company could quickly become a leader in cannabis supply-chain logistics. Management also remains committed to growing shareholder value over the long run, and ultimately becoming a dominant player in the space.

“To investors, we promise to work tirelessly on their behalf and for the long-term growth of BLOCKStrain, ensuring this is the best tech company in the sector, and one that provides you with a solid and sound investment,” said CEO Robert Galarza.

Investors may want to take note sooner rather than later as this stock only recently began trading on the TSX Venture exchange.

For more information please visit the company’s website: http://blockstrain.io

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Exclusive: BLOCKStrain CEO Outlines Blockchain’s Potential Role in Cannabis appeared first on CannabisFN.

Maricann: A Unique & Undervalued Licensed Producer with a Global Focus

Written by Ryan Allway on

Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the upcoming legalization of adult-use cannabis. While there are more than 100 licensed producers approved by Health Canada, there are only a handful of companies that are really well positioned in the space with differentiated products and a focus on global export market rather than just the domestic market.

Maricann Group Inc. (CSE: MARI) has built up a global presence in both Canada and Europe with rapidly expanding production and numerous differentiating factors. Despite its rapid expansion and diversification, the company trades at a fraction of the value of other licensed producers in the space, which makes it a compelling opportunity for investors.

Optionality & Diversification

Maricann Group has built a strong presence in Canada, Germany, and Switzerland with plans to expand throughout Western Europe. For example, the company recently signed a letter of intent to acquire Medican Holdings Ltd., which is located in the Republic of Malta. The company is one of six to receive a license to import, extract, manufacture, and distribute cannabis for medical purposes within Malta and throughout the European Union.

In addition to its geographic diversification, the company operates a diverse line of businesses, including both medical and recreational cannabis (when legal in Canada), as well as nutraceuticals and inhalants. The company’s medical cannabis business is primarily driven through its partnerships with large pharmacy chains, such as Lovell Drugs Ltd., while its recreational business is being spearheaded by the former Head of Marketing for Diageo Canada, Geoff Kosar.

The nutraceuticals business is primarily focused on entering the $3 billion cannabidiol (CBD) market in Europe through its high-quality and differentiated product (www.mariplant.de). In a related push, the company’s acquisition of Haxxon in Switzerland represented a creative way to address the growing market for inhalant CBDs created using hemp, which have become a popular alternative to tobacco given the potential health benefits.

Ramping Up Production

With Canadian adult-use legalization looming, many analysts predict an initial shortfall in the market. Licensed producers have attempted to scale up their production, but the reality is that few will be ready with enough product when the new measure goes into effect. The good news is that licensed producers with enough supply will be able to satisfy the demand from the provinces and ensure repeat orders as shelf space needs to be restocked.

Maricann plans to have 25,000 kilograms of annual production capacity online by late Fall of 2018 which will place the company amongst a small group of producers with similar capabilities. Medium and long-term plans include an expansion of their facility to 942,000 square feet with the capacity to produce upwards of 95,000 kilograms per year. These figures are much higher than other licensed producers that are trading at very lofty valuations, which makes the company incredibly undervalued and provides investors a unique opportunity to capitalize on this disconnect in the market.

Unique Differentiators

Maricann Group is one of only six licensed producers with an EMA-GMP certification, which means their dried flower is deemed acceptable to be exported into the very attractive European market. Due to these high barriers to entry, prices in the EU for medicinal cannabis are 4-5 times higher than they are in Canadian market, which makes having this certification highly coveted.

In addition to its industry-leading manufacturing practices, the company owns the global rights for cannabis to a patented drug delivery technology, known as VesiSorb. The same technology is already used in about 40 percent of the world’s lipophilic (fat soluble) drugs to address the oil and water solubility issue and address problems with the onset of active ingredients. It’s technology can be used in a wide range of applications including functional beverages and topical ointments, just to name a few.

These unique differentiators set the company apart from other companies in the space that are focused exclusively on mass producing cannabis flower.

Looking Ahead

Maricann Group Inc. (CSE: MARI) represents a compelling investment opportunity within Canada’s burgeoning cannabis industry. With its large geographical footprint, diverse product lines, and rapidly scaling production levels, the company is well positioned to take advantage of rising global demand for cannabis across Canada and Europe. Investors may want to take a closer look at the stock given its many near-term catalysts and compelling valuation.
For more information, visit the company’s website or download their investor presentation.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Maricann: A Unique & Undervalued Licensed Producer with a Global Focus appeared first on CannabisFN.

Friday Night Inc. Signs Licensing Agreement with Poker Champion Scotty Nguyen

Written by Ryan Allway on

VANCOUVER, May 28, 2018  /CNW/ – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF), a leading cannabis, hemp and CBD producer in Nevada, and its subsidiary, Infused MFG, are pleased to announce a one-year licensing agreement (the “Agreement”) with professional poker player, Mr. Scotty Nguyen, for the launch of Canna Hemp™ branded products co-marketed under his name.

Friday Night Inc. (CNW Group/Friday Night Inc.)

The Agreement includes the launch of two CBD-infused products created with a special blend of terpenes selected for their acute mental concentration properties:  Scotty Nguyen “Focus Baby” Disposable Vape Pen and “Focus Baby” Elixir. These products will be unveiled on Tuesday, May 29th, 2018, to coincide with the 49th Annual World Series of Poker taking place in Las Vegas, Nevada, and will be sold through current dispensaries, retail stores and online at www.focusbabycbd.com.

“We are pleased to have the endorsement of poker legend Scotty Nguyen. Partnering with Scotty opens a new market vertical for Canna Hemp™ CBD products with a target audience not only at the WSOP but for anyone desiring innovative, all natural health solutions”, said Mr. Chris Rebentisch, President and CEO of Infused MFG. “We are witnessing increasing demand for our Canna Hemp™ products in both Nevada and California, where Canna Hemp™ is now carried in more than 30 Californian dispensaries alone”, he added.

Mr. Thuận B. “Scotty” Nguyen is the first and currently only player to win both the WSOP Main Event and the Players’ Championship. He is a five-time World Series of poker (WSOP) bracelet winner, most notably as the winner of the 1998 World Series of Poker Main Event and the 2008 World Series of poker H.O.R.S.E. World Championship.

“I am very excited about the release of the “Focus Baby” Elixir and CBD Vape pen with Canna Hemp™. I love to be a part of something that I believe in and can attest to its effectiveness,” commented Mr. Nguyen. “I have seen a marked difference in myself while using the Canna Hemp™ products, especially the “Focus Baby” line. I’ve got big goals this year and the “Focus Baby” CBD will definitely help me reach those goals.”

About Canna Hemp™ “Focus Baby”

With a special blend of terpenes selected for their acute mental concentration properties, the Focus Baby CBD vape pen and elixir are the only products endorsed by “The Prince of Poker” Scotty Nguyen to give him an extra edge when he wants to go all-in. The pre-loaded, disposable, THC-free Focus Baby pen includes mood-boosting Limonene, memory aid a-Pinene, and increased mental and physical energy from Eucalyptol and has enticing hints of grapefruit, followed by an earthy aftertaste for an enjoyable and stimulating experience when the chips are down.

About Friday Night Inc. 

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada as well as an international cannabis and mining security logistics consulting firm. The Company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands. Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients. The Company’s wholly-owned subsidiary, Spire Secure Logistics is a leading provider of customized security programs, compliance, information technology, buildout design, and due diligence services for the legal cannabis, mining and investment sectors. Friday Night Inc. is focused on strengthening and expanding its current operations.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/friday-night-inc-signs-licensing-agreement-with-poker-champion-scotty-nguyen-300655386.html

SOURCE Friday Night Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2018/28/c6649.html

Alexia Helgason, Corporate Communications, 604-674-4756 (ext. 1), Alexia@FridayNightInc.com; Brayden Sutton, Director/President & CEO, 604-674-4756 (ext. 1)Copyright CNW Group 2018

 

Source: Canada Newswire (May 28, 2018 – 8:30 AM EDT)

The post Friday Night Inc. Signs Licensing Agreement with Poker Champion Scotty Nguyen appeared first on CannabisFN.

High Hampton Secures Distribution in California

Written by Ryan Allway on May 25, 2018

California’s cannabis industry is projected to exceed $5 billion in size next year, creating a significant opportunity for investors. While most people are familiar with cultivators, dispensaries, and growtech providers, distribution is an often underappreciated part of the cannabis space. These companies provide marketing and logistical services to connect the various parties involved in delivering products to consumers.

High Hampton Holdings Corp. (CSE: HC), an investment company focused on opportunities in California, recently signed a binding term sheet with a leading distributor in California to help address these challenges and provide investors with exposure to this key area.

California’s Growing Market

California just started selling adult-use cannabis at the beginning of the year and analysts already expect billions in revenue. The state’s cannabis sales could hit $3.7 billion by the end of this year and reach $5.1 billion next year as more dispensaries come online, according to BDS Analytics. By comparison, the state’s beer revenues totaled just $5 billion in 2017, according to IBIS World, which demonstrates the scale of the legal cannabis opportunity.

As the fifth largest economy in the world with a population of nearly 40 million, California has become the single largest cannabis market in the world. BDS Analytics notes that ex-California cannabis revenue topped $9.7 billion in the United States and Canada last year, but that figure is expected to rise to $24.5 billion by 2021 with the inclusion of California. These figures translate to a very attractive opportunity for companies and their shareholders.

The state also has strong support from lawmakers. For example, California Treasurer John Chiang – who is also a candidate for governor – agreed to work with Attorney General Xavier Becerra to study the legal questions surrounding the creation of a cannabis public bank. Such an institution would solve a key challenge facing the cannabis industry: The lack of regulated access to the banking system, which complicates everything from credit card payments to taxes.

Another key challenge facing California’s nascent cannabis industry are services that are typically provided by distributors in the beer, wine, and spirits business. These distributors provide sales, marketing, transportation, and supply chain management services and work with dispensaries, delivery services, and chain stores, as well as manufacturers, cultivators, clinics, universities, and the many other entities that are involved in the industry.

High Hampton’s New Acquisition

High Hampton recently announced that it entered into a binding term sheet with 8 Points Management LLC and its Bravo Distro subsidiary to acquire 100% of all the issued and outstanding shares of both companies in an all-stock transaction. The two companies expect to enter a definitive agreement on or before June 6, 2018, subject to a number of conditions including the completion of the share exchange.

“Securing distribution is a crucial if not the most important component of a successful business model for the California cannabis market,” said High Hampton CEO David E. Argudo. “In 8 Points Management we have found a well-positioned operator that offers a full-service distribution model for our industry that will help us establish access to major distribution hubs in strategic locations throughout California, including a prominent location in West Sacramento.”

“Through this acquisition we will position ourselves and act as an inventory clearinghouse for retail and other cannabis businesses since it is not feasible for the majority of the companies to do their own distribution. We will serve multiple roles such as:

  • collecting taxes and fees for the state
  • being a sales and marketing engine for customers
  • having the opportunity to incorporate processing facilities
  • pick up, dry, cure, process, package, bottle and distribute brands

By cross pollinating the different opportunities within distribution, High Hampton will create centralized hubs that will maximize value for our shareholders.  8 Points Management’s/ Bravo Distro’s acquisition aligns with this strategy by bringing the core talent and experience to achieve our goal.”

Bravo is a fast-growing California cannabis distributor founded by the same team that served as the brainchild for one of the first companies in California to receive a permit for medical cannabis wholesale logistics, distribution, and transportation. The deal provides the company with immediate access to a major distribution hub in California, a team of alcohol distribution veterans, and lays the foundation for building out a leading distribution network in the state.

Looking Ahead

High Hampton Holdings Corp. (CSE: HC) represents a compelling investment opportunity in California’s nascent cannabis industry. In addition to its new potential acquisition, the company owns a 10.8-acre property in Coachella, CA that it plans to develop into a cannabis industrial park. The company has received approval from the Coachella Planning Commission for a Conditional Use Permit (CUP) which allows the company to begin construction of a full service production facility.
For more information, visit the company’s website or download their investor presentation.

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post High Hampton Secures Distribution in California appeared first on CannabisFN.

Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis

Written by Ryan Allway on

Toronto, Ontario–(Newsfile Corp. – May 25, 2018) – Canntab Therapeutics Limited (CSE: PILL) (formerly Telferscot Resources Inc.) (“Canntab” or the “Company”) is pleased to announce that it continues to expand its extensive intellectual property portfolio through the recent filing of 2 additional Canadian patent applications. Canntab’s portfolio now includes 13 patent applications in Canada, the United States and internationally. These filings build on Canntab’s growing intellectual property portfolio, which already included patent applications and trademark applications in the United States and Canada. The new Canadian patent applications that were filed pertain to a variety of Canntab’s innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including Sustained Release Cannabinoid Formulations and Sustained Release Cannabinoid Pellets.

Previously filed applications relate to Immediate Release Cannabidiol Formulations; Modified-Release Multi-Layer Cannabinoid Formulations; Flash-Melt Cannabinoid Formulations; and Bi-layer Cannabinoid Tablets.

These patent applications are part of Canntab’s continuing strategy to develop a comprehensive intellectual property portfolio which covers the company’s technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, which includes a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that may be helpful in the treatment of a number of ailments, such as

sleep disorders;
post-traumatic stress disorder (PTSD);
social anxiety;
addiction;
arthritis;
general pain;
pain management and appetite loss associated with cancer treatments; and
addiction treatment therapy of opioids and other painkillers.

Canntab is currently in the process of seeking approval from Health Canada for its extended release tablets and making batches of the tablets for third-party clinical trials in Canada. The company also plans to enter the United States market by obtaining a manufacturing and distributors license in certain US states.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in- house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited Richard Goldstein, CFO Office: 416 957-6303 info@canntab.ca

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward- looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this press release.

copyright (c) newsfile corp. 2018
Source: Newsfile Corp. (May 25, 2018 – 10:03 AM EDT)

The post Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis appeared first on CannabisFN.

Speakeasy Appoints Brian Peery of Hennessy Funds to Advisory Board

Written by Ryan Allway on

VANCOUVER, May 25, 2018 /CNW/ – Speakeasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “Speakeasy”) a late stage ACMPR applicant is pleased to announce it has appointed Mr. Brian Peery to its board of advisors.

Mr. Peery currently manages in excess of $3 Billion as a Portfolio Manager with Hennessy Funds.  Prior to his current role, Mr. Peery served a number of roles, including institutional sales, trading, research, and analysis before becoming a Portfolio Manager in 2011.  Prior to joining Hennessy Funds in 2002, Brian worked for a boutique investment firm as an equities analyst and went on to manage research and trading for a full-service brokerage firm. Mr. Peery holds a BA in Economics and English from the University of Richmond.

“I am very pleased with today’s appointment of Brian to our Advisory Board. Mr. Peery’s brings an in-depth knowledge of the capital markets and access to a world class financial network with the ability to put the Company in front of the highest level of investors and instiutions. Brian has been featured on CNBC, CNN and Reuters,” stated Marc Geen, CEO.

About Speakeasy Cannabis Club Ltd. (CSE:EASY)

Speakeasy Cannabis Club Ltd. is a late stage ACMPR applicant that is leveraging three generations of farming experience and the largest land package of LP in Canada with 290 acres of the best agricultural land in British Columbia’s Southern interior region; known as the Napa Valley of weed country. Speakeasy is disrupting the cultivation model by aggregating British Columbia’s best craft growers under one umbrella to produce the highest quality cannabis targeted at the highly sought after millennial recreational market.

Speakeasy has submitted its extensive evidence package to Health Canada for its current 10,000 square feet facility and has commenced construction on its 80,000 square feet expansion facility. This 80,000 square foot facility will include growing, extraction and genetics labs.

ON BEHALF OF SPEAKEASY CANNABIS CLUB LTD.

(signed) “Marc Geen“

Chief Executive Officer

Not for distribution to United States wire services or dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Statements about the Target’s future facility expansion plans or ACMPR license application are all forward-looking information.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Speakeasy Cannabis Club Ltd.

View original content: http://www.newswire.ca/en/releases/archive/May2018/25/c5395.html

Please contact Speakeasy Cannabis Club Ltd., www.speakeasygrowers.com, Telephone: 604-283-1722Copyright CNW Group 2018

 

Source: Canada Newswire (May 25, 2018 – 3:05 AM EDT)

The post Speakeasy Appoints Brian Peery of Hennessy Funds to Advisory Board appeared first on CannabisFN.

The Cross Pollination of Cannabis Investments in North America

Written by Ryan Allway on

The cannabis industry is one of the fastest growing industries in North America. The legalization of medical and adult-use cannabis helped the industry grow more than 30 percent in 2016 to nearly $10 billion last year, according to ArcView Group, and there are no signs of a slow down. By 2021, the Oakland, CA-based research firm believes that the market could exceed $24.5 billion, representing a blistering 28 percent compound annual growth rate.

In this article, we will look at how cannabis companies and cannabis-focused investors have navigated opportunities in both the United States and Canada.

Canada’s Favorable Regulations

Canada legalized medical cannabis under the Marijuana for Medical Purposes Regulations, or MMPR, back in 2013, making it the first G20 country to federally legalize the drug. With the election of Justin Trudeau as Prime Minister in 2015, voters green-lighted the legalization of adult-use cannabis on a federal level as well under what’s now known as a the Access to Cannabis for Medical Purposes Regulations, or ACMPR.

By comparison, the election of Donald Trump in November of 2016 brought a lot of uncertainty to the cannabis industry, especially with the appointment of Jeff Sessions as attorney general. Lawmakers in the House and Senate have made a lot of progress in moving towards a federal framework – at least for medical cannabis – but the country has a long way to go before its regulations reach the maturity of Canada.

While many North American industries are concentrated in the United States, Canada’s progressive policies have helped create the largest companies in the cannabis industry. Canopy Growth Corp. (TSX: WEED), Aurora Cannabis Inc. (TSX: ACB), and several other licensed producers have amassed multi-billion dollar market capitalizations by cultivating cannabis for the domestic market and for export all around the world.

The regulatory environment is so favorable that many U.S. companies have opted to go public in Canada to avoid federal intervention in the United States. For example, California-based MedMen Enterprises, which operates dispensaries and production facilities in three states with about 700 employees, plans to go public in Canada through a reverse takeover with a listed shell company rather than an initial public offering.

Growing Appetite for U.S. Exposure

The corollary is that there is strong global investor appetite for U.S. cannabis companies – and especially those with exposure to California’s massive market. In November 2016, California voters legalized adult-use cannabis in a move that created the world’s largest single market. ArcView Market Research believes that the market will grow from $2.8 billion in 2016 to $6.5 billion by 2020, representing a strong 23.1 percent compound annual growth rate.

“The Canadian public market offers access to a lot of capital, with a lot of certainty and a lot of speed, and there is this appetite among global investors to invest in a U.S. play,” said MedMen CEO and Co-Founder Adam Bierman at the Canaccord Genuity conference in Vancouver this year. “Specifically, global investors want to invest in a U.S. play that has California exposure. Now is the time where it makes the most sense.”

Many Canadian licensed producers trade at lofty valuations by conventional earnings metrics, while there is growing uncertainty about the true size of the domestic market. With over 100 licensed producers (and counting) approved by Health Canada, the growing supply could lower prices and create thinner profit margins than investors were initially expecting to see. Those dynamics have led many Canadian investors to look at ancillary opportunities.

Looking Ahead

Investors may want to take a closer look at U.S. companies focused in California as an opportunity to diversify licensed producer holdings in Canada. MedMen Enterprises is a great example, particularly given its size and growth, as it looks to go public through a reverse merger.

The post The Cross Pollination of Cannabis Investments in North America appeared first on CannabisFN.

RISE Life Science: Commitment to the Highest Quality Cannabis Products for Sexual Health and Wellness

Written by Ryan Allway on May 24, 2018

As the cannabis industry matures, both in North America and across the globe, regulations and consumer demands will require companies to produce consistent, high quality products that are safe and effective. Gone are the days of illicit weed grown with questionable practices, as the black market is being replaced by regulated operations offering a variety of cannabis products scientifically developed for use in distinct applications. With the wide variety of strains and chemical profiles now available to companies making legal cannabis products, a commitment to sourcing quality plants and developing scientifically researched products tailored for a range of needs is more important than ever.

RISE Life Science Corp. (CSE: RLSC) is a prime example of a company committed to quality from start to finish. RISE is creating a line of cannabis-derived sexual health and wellness products that it intends to market globally, starting in California. From sourcing the best cannabis strains, to rigorous research and development standards, to the commencement of a major cannabis/sexual health study, the company is committed to the highest standards throughout the entire life cycle of product development.

Quality Starts with the Plant

Working toward the highest level of quality, RISE plans to use the best plant sources for the consumer products it develops. As such, the company is exploring a comprehensive supply partnership with Jamaican premium strain producers who meet standards for CGMP (current good manufacturing processes) as set out by the FDA. These standards are designed to assure that quality is built into the design and manufacturing process at every step; facilities are in good condition; equipment is properly maintained and calibrated; employees are qualified and fully trained; and, processes are reliable and reproducible.

Jamaica is not only considered one of the best growing regions in the world, it is also viewed as one of the most experienced, producing cannabis for well over 400 years. With such a deeply established botanical relationship it is no surprise that Jamaican marijuana strains are widely recognized as some of the highest quality in the world.

RISE is targeting strains with the appropriate terpene and cannabinoid profiles to form the basis for its medical line of products to ensure that only the highest quality raw material is utilized in the formulation and development process.

Laboratory Science Important for RISE

RISE Life Science is partnered with experts in the manufacture of premium medical cannabis extract products for physician and patient use. They are leveraging deep experience with whole plant extracts utilizing proprietary extraction and compounding methods.

RISE is launching in California, but has its eyes on markets around the world. International certification is important for companies pursuing global market opportunities. With a patchwork of regulatory demands across markets, the company is seeking the highest-regarded quality control standards in another indication of RISE’s commitment to quality and global acceptance for its products.

“Validated science is at the core of our product development,” said Anton Mattadeen, CEO of RISE. “Our focus is on producing pharmaceutical grade product derived from highly-controlled processes that are continually supported by a feedback of observational data.”

The formulations of RISE products also draw heavily from botanical traditions. To this end, the company’s product formulation strategy relies on herbal specialists based out of Colorado. RISE’s lead herbalist brings 30 years of experience to the company’s product development.

Sexual Health Study Underpins Product Development

Future products will be developed with insights gained from a proprietary research study RISE will launch this fall. It will be the largest observational study of its kind, looking at the effect of cannabis health products on sexual health, behaviors, and performance.

The RISE Report on Cannabis and Sexual Health and Wellness intends to answer many questions that have gone unanswered, and unstudied, as a result of the long-term prohibition of cannabis and research related to the plant. Starting with about 200 beta participants, the study will expand to thousands of people and the data derived should be valuable in a number of ways.

“We are investing in this study because it is central to the ongoing development of consumer products that individuals and couples believe in and actually want to use,” continued Mattadeen. “The proprietary data generated by this study will not only add necessary information to the subject of sexual health, it will also inform RISE of the best possible product development decisions to meet the needs of our customers, provide us with a competitive advantage in the marketplace, and help us remain right in the middle of this important conversation with our expanding consumer community.”

For RISE, the most obvious benefit will lie in how the findings can inform and improve the company’s own product development. The company views this outcome as a competitive advantage in a market rife with un-researched products and wild claims of efficacy. The data would also add more generally to the growing library of science surrounding cannabis, potentially adding more credence to the idea of using the plant as a legitimate treatment and eliminating some of the social taboos around both marijuana and sex.

All told, RISE Life Science is demonstrating its commitment to quality ingredients, practices, and products based on the science of cannabis. With an initial product launch coming soon in California, keep an eye out for further developments in RISE’s quest to legitimize cannabis as a tool to improve lives of consumers and patients wherever the law allows.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post RISE Life Science: Commitment to the Highest Quality Cannabis Products for Sexual Health and Wellness appeared first on CannabisFN.

Crop Infrastructure Announces OTC Ticker Symbol Change to “CRXPF”

Written by Ryan Allway on

VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) — CROP Infrastructure Corp. (the “Company”) (CSE:CROP) (OTC:CRXPF)  announces a change in the Company’s stock symbol trading on the OTC Markets. Effective today, May 24, 2018, the Company’s common shares will trade on the OTC Markets under the symbol “CRXPF”. The previous trading symbol was “CIICF”.

There is no action required by current shareholders in connection with this change.

About CROP Infrastructure Corp.

CROP Infrastructure is engaged in the business of investing, constructing, owning, optimizing and branding light supplemented greenhouse projects for lease to cannabis producers and processors offering best-in-class operations. The Company’s main focus is currently California and Washington.

For more information and to register to CROP’s mailing list, please visit www.cropcorp.com. Follow CROP on Instagram @CROPCORP and on twitter @CROP_cse.

For further information, please contact:

Crop Infrastructure Corp.
Alex Horsley, Director
Tel: 604-484-4206
E-mail: info@cropcorp.com

The securities of the Company are considered highly speculative due to the nature of the Company’s business. The Company is indirectly involved through its business in both the medical and recreational cannabis industry in the United State where local state law permits such activities. As a result of the conflicting views between state legislatures and the federal government regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation and therefore there are risks of federal government enforcement. Marijuana-related practices or activities, including the cultivation, possession or distribution of marijuana, are illegal under U.S. federal law.

Forward-Looking Statements

Certain statements in this release are forward-looking statements, which include regulatory approvals, the business of the Company and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. Forward-looking statement are necessarily based upon a number of factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

 

Source: GlobeNewswire (May 24, 2018 – 9:16 AM EDT)

The post Crop Infrastructure Announces OTC Ticker Symbol Change to “CRXPF” appeared first on CannabisFN.

Key Analyst Joins Leading U.S. Cannabis Company

Written by Ryan Allway on
Los Angeles (May 24, 2018) – MedMen Enterprises has hired Vahan Ajamian, one of the leading financial analysts in the emerging cannabis industry, as its new managing director of analyst relations.
Named one of the “rising stars in the marijuana investment scene” by Business Insider, Ajamian has more than a decade of experience in equity research and analysis. A capital market forerunner in the cannabis sector, he was one of the first to cover Canada’s growing list of publicly traded cannabis companies and is an expert on the U.S. sector.
Cannabis is the fastest growing industry in North America. It had sales of $9.2 billion in 2017 and is expected to grow to $47.3 billion by 2027, according to BDS Analytics. As the industry matures, cannabis companies have increasingly sought to raise capital via the public markets. The more established companies have listed on bona fide exchanges in Canada and the U.S. like the New York Stock Exchange, the Nasdaq, the Toronto Stock Exchange and the Canadian Securities Exchange. Ajamian will be MedMen’s principal liaison with brokers and financial analysts covering investment opportunities in the cannabis space.
“The cannabis industry needs professional expertise at all levels and MedMen has been assembling the best talent in every field,” said MedMen CEO Adam Bierman. “Vahan is a respected voice of authority in the cannabis sector, and we are proud to have him represent MedMen.”
Prior to joining MedMen, Ajamian was an equity research analyst at Beacon Securities, a full-service independent investment firm with offices across Canada. He was the first analyst to report on the broader U.S. cannabis sector and was frequently cited by both investors and news media publications. Prior to Beacon Securities, Ajamian was an equity research associate at TD Securities.

“Cannabis is an exciting, fast moving space and MedMen is leading the charge,” Ajamian said. “I am proud to be joining a company that is defining the industry.”

About MedMen:
MedMen Enterprises is the preeminent cannabis company in the U.S. and the most recognized brand in the emerging marijuana industry, with assets and operations in key markets. Based in Los Angeles, MedMen employs more than 800 employees, and is the single largest financial supporter of progressive marijuana laws. Visit http://www.medmen.com.
Media Contact:
Briana Chester
1-424-465-4419

The post Key Analyst Joins Leading U.S. Cannabis Company appeared first on CannabisFN.

Future Farm’s NexTech AR Solutions Acquires Exclusive License to Education Training Platform Accelerating its Launch

Written by Ryan Allway on

Future Farm has secured an exclusive, five-year license to edCetra, the eLearning education and training platform

Vancouver, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that NexTech AR Solutions (“NexTech”), the augmented reality company it plans to spin off, has secured an exclusive, five-year license to the eLearning education and training platform developed and offered by edCetra Training Inc. (“edCetra”). In addition, NexTech will have an option to buy edCetra itself for the next 12 months.

NexTech issued edCetra 100,000 common shares of NexTech stock at a deemed value of CDN$0.25 per share as the consideration for the exclusive license.  If NexTech elects to exercise its option to purchase edCetra, the consideration will be an additional 100,000 shares, provided that the value of the shares at the time of exercise is at least CDN$0.25 per share.

edCetra has reported to NexTech that the platform has been used by Fortune 500 companies such as Imperial Oil, Bombardier and Staples, as well as the Library of Congress and others to educate and train employees. By licensing the technology, NexTech can accelerate its business plan and will spend the next few months customizing it to create an augmented reality (“AR”) training and education platform for the cannabis industry, with a plan to expand into other industries in the future. The new augmented reality platform is expected to launch in the next 90 days.

The use of augmented reality as a training and education tool is expected to be a major growth driver for the AR industry. NexTech’s management anticipates it will have a first mover advantage since it will provide customization and upgrades to an existing platform. The edCetra license includes the following features and functionality:

  • Fully realized learning on demand system
  • Supports multiple file types (video, webinar, text, PDF)
  • Pay as you go, and subscription enabled
  • Allows for multiple business models supporting retailers, wholesalers and publishers
  • Set any price for any piece of content
  • Out of the box reporting

Core features of the system include digital asset management, user administration, e-commerce and content delivery. Reuben Tozman, President and founder of edCetra and an expert in the field of educational technology who recently joined NexTech’s board of directors, comments, “I am excited to be a part of this next generation platform and help NexTech’s technology bring AR to education and training. I see a lot of demand and a bright future for this.”

The augmented reality market is set to grow substantially in the near future as companies such as Apple, Google, Microsoft and Intel are now aggressively launching software and hardware to support this dynamic and fast-growing industry. According to ResearchAndMarkets.com, spending is projected to jump from $11.14 billion in 2018 to $60.55 billion by 2023, representing a compound annual growth rate of 40%.

Once the spinoff is complete, Future Farm shareholders will own shares in NexTech AR Solutions, a newly formed company occupying a valuable niche in the cannabis market with augmented reality-enhanced packaging as well as an ad-tech driven platform featuring a virtual budtender for dispensaries.

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman and CEO

About Future Farm Technologies Inc. 

Future Farm is a Canadian company with holdings throughout North America including California, Massachusetts, Florida, Maine, Puerto Rico and Newfoundland. The Company’s mission is to advance sustainable agriculture through production of wholesale and retail cannabis products, including hemp. As a leader in its field, Future Farm is committed to using only the highest quality processes and products. Towards this goal, the Company acquires or partners with licensed cannabis operators, and acquires or develops leading technologies in cannabis production, breeding, genetics, and Controlled Environment Agriculture (CEA). Future Farm’s scalable, indoor CEA systems utilize minimal land, water and energy resources. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

William A. Gildea
6178349467
BILL@FUTUREFARMTECH.COM

Primary Logo

 

Source: GlobeNewswire (May 24, 2018 – 8:00 AM EDT)

The post Future Farm’s NexTech AR Solutions Acquires Exclusive License to Education Training Platform Accelerating its Launch appeared first on CannabisFN.

Abattis and Vergence Naturals Launch New Marketing Campaign

Written by Ryan Allway on

VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) and its wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence”), have launched their “Live. Love. Life. Naturally!” marketing campaign to build awareness for their naturally inspired health and beauty brands for the conventional and cannabinoid-enhanced markets.

The campaign is designed to promote the products and services of Vergence and the Company’s other affiliates.  “We are very pleased with the consistent progress being made through our marketing and distribution arm, Vergence,” stated Rob Abenante, President and CEO of Abattis. “With the appointment of Dr. Brazos Minshew as Head of the Company’s Medical Advisory Board and President of Vergence’s Corporate Advisory Board, we look forward to the development of new formulations and innovative natural products for the conventional and cannabinoid-enhanced markets,” added Mr. Abenante.

Product Development

All Vergence products are selected to help clients enjoy and maximize their quality of life, naturally!  Vergence’s lifestyle divisions include: natural health (food and personal care); beverages; pharma and nutraceuticals; and spa and beauty, with a unique selection of raw, clean and natural products.

Vergence ensures that its products are safe, crafted from natural ingredients and fully supported by medical and market research. For further information respecting Vergence’s product offerings, please visit http://vergencenaturals.com/ and follow Vergence on Facebook, Twitter and Instagram.

Campaign Description and Rewards

Live healthy, live longer and enjoy life.

A healthy lifestyle at any age includes habits that help you live longer and enjoy a superior quality of life.  At VERGENCE we want to know how you LIVE. LOVE. LIFE. NATURALLY!

Do you run, walk, hike, golf, garden or do yoga?  Share your favorite pictures, inspirational quotes, fitness routines, recipes etc. and you can win some fabulous prizes!  Complete the tasks, earn points to enter our draw (1 point = 1 entry) and be rewarded!  Share or post your entries via Email, Facebook, Instagram or Twitter to win.

Prizes include:

  • 15% off coupons at the Vergence online store
  • featured Vergence product samples
  • Vergence branded merchandise and featured products
  • Vergence gift boxes
  • LIVE. LOVE. LIFE. Naturally! Luxury themed gift boxes

Visit Vergence’s website at https://vergencenaturals.com/ for more details and to enter the draw.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at info@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Primary Logo

 

Source: GlobeNewswire (May 24, 2018 – 9:12 AM EDT)

The post Abattis and Vergence Naturals Launch New Marketing Campaign appeared first on CannabisFN.

BLOCKStrain trading begins on TSXV under symbol DNAX

Written by Ryan Allway on May 23, 2018

VANCOUVER, May 23, 2018 /CNW/ – On behalf of BLOCKSTRAIN TECHNOLOGY CORP. (TSXV: DNAX) (formerly Scorpion Resources Inc.) (NEX:SR.H) (the “Company“), we’re pleased to announce that trading began today in shares of our company on the TSX Venture Exchange (“TSXV“) under the stock symbol ‘DNAX.’

BLOCKStrain Technology Corp. (CNW Group/BLOCKStrain Technology Corp.)

This is a big day for our team, and is the culmination of many years of preparation and dedication to building a software company designed exclusively to meet the unique needs and challenges of the emerging cannabis industry.  We have combined the best of enterprise and decentralized ledger technology to launch the first integrated blockchain platform that registers and tracks intellectual property for the cannabis sector.

BLOCKStrain offers a comprehensive, community-driven cannabis genetics registration and licensing archive platform dedicated to making it safe and comfortable for breeders and growers, large and small, to protect and release their cannabis varieties into the public domain. Our software is designed to provide verification and transparency in the marketplace in order to ensure a safe and legal pipeline of inventory between the producers and consumers.

Additionally, we designed our platform to streamline and automate the testing process for cannabis, a regulatory requirement that we expect will become more onerous once recreational marijuana becomes legal in the Canadian market. Our mission is to support the growth of this industry by providing tools that maximize efficiency and eliminate redundancies. By combining our platform with some of the largest testing labs in North America, we aim to cut administrative time and costs in half.

If you are a grower, cultivator or producer of legal cannabis, and you want to protect your intellectual property or have your product tested, we want to hear from you. We also want to hear from any and all technology companies that are interested in working with us to further innovate technology for the evolving needs of the growing cannabis industry.

To investors, we promise to work tirelessly on your behalf and for the long-term growth of BLOCKStrain, ensuring this is the best tech company in the sector, and one that provides you with a solid and sound long-term investment.

Stay tuned for more news. Today’s announcement is the first of many great things to come.

Robert Galarza
Chief Executive Officer and Director

and

Tommy Stephenson
Chief Technology Officer

About BLOCKStrain Technology Corp.

BLOCKStrain Technology Corp. (TSX-V: DNAX.V) has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry. Strain protection and genetic identification are major issues for growers and breeders, and this new technology allows them to identify and secure rights to their valuable intellectual property (IP). The BLOCKStrain platform also streamlines the administrative process of genetic and mandatory quality-control testing for legal cannabis, cutting the administrative time and expense in half.

BLOCKStrain’s proprietary, immutable, cryptographically-secure blockchain-technology establishes a global ‘single source of truth’ for cannabis strains, their ownership, potency and chemical makeup. In an industry where a popular strain can be worth millions of dollars, it is crucial to the industry’s future to quantify genetics, potency and equivalencies between cannabis products. BLOCKStrain delivers needed transparency to growers, retailers, regulators, and consumers who have struggled to find realistic solutions to these logistical challenges. The good news is that the blockchain technology implemented by BLOCKStrain is ideally suited to solve these kinds of problems by implementing an immutable and non-corruptible record of transactions.

ON BEHALF OF THE BOARD OF DIRECTORS

“Robert Galarza”

Robert Galarza
Chief Executive Officer and Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the expected benefits of, and impact on, the cannabis industry as a result of BLOCKStrain’s technology; other statements regarding the business of BLOCKStrain; that BLOCKStrain will support the growth of the cannabis industry; that its platform will be able to cut administrative time and costs in half; and management’s goals with respect to making BLOCKStrain the best technology company in the cannabis sector that provides a solid long-term investment. Such statements are based on management’s current assumptions with respect to the regulatory environment for cannabis, the expected applications of its technology and other factors, and are subject to various risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: BLOCKStrain’s platform may not operate as expected; the cannabis industry may not use the BLOCKStrain platform once it is built; legislative changes may occur that negatively impact BLOCKStrain’s business; BLOCKStrain’s platform may not adequately protect users’ intellectual property; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE BLOCKStrain Technology Corp.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2018/23/c2379.html

Paula Arab at (403) 889-9128 or paula.arab@blockstrain.ioCopyright CNW Group 2018

The post BLOCKStrain trading begins on TSXV under symbol DNAX appeared first on CannabisFN.

Lexaria Bioscience Corp. Receives New Granted Patents

Written by Ryan Allway on

KELOWNA, BC / ACCESSWIRE / May 23, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th.

Once granted, Lexaria will have 4 granted patents in the US and 4 granted patents in Australia. All eight of these patents are within Lexaria’s first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”, and significantly strengthen Lexaria’s intellectual property (“IP”) claims in the US and Australia.

Of note, the new Australian patents expand Lexaria’s IP protection to include the delivery of all cannabinoids, psychoactive and non-psychoactive; nicotine; NSAIDs including but not limited to ibuprofen; and fat-soluble vitamins such as vitamins A, D, E, and K. This represents the first time that Lexaria has received patent protection for delivery of molecules other than cannabinoids outside of the US.

Lexaria’s patent portfolio continues to grow, now with more than 40 patent applications or awards in over 40 countries around the world. Additional new patent application filings for new patent families as a result of R&D programs are currently being prepared and Lexaria continues to expect further patent awards this year. As its patent portfolio expands, Lexaria will be better able to commercialize its technologies and defend its intellectual property.

Separately, Lexaria announces it has received US$24,500 from the exercise of warrants previously granted. The Company has received for exercise a total of 175,000 warrants with an exercise price of US$0.14, previously granted. The warrant exercises are by a third party who is neither an officer nor a director of the Company.

No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

The securities referred to herein will not be or have not been registered under the United StatesSecurities Act of 1933, as amended, and may not be offered or sold in theUnited States absent registration or an applicable exemption from registrationrequirements.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

TheCSE has not reviewed and does not accept responsibility for the adequacy oraccuracy of this release.

SOURCE: Lexaria Bioscience Corp.

The post Lexaria Bioscience Corp. Receives New Granted Patents appeared first on CannabisFN.

NanoSphere Health Sciences Wins Prestigious Frost & Sullivan 2018 Technology Innovation Award

Written by Ryan Allway on

Nano-Biotechnology Firm Recognized for its Next-Generation Medical Delivery System in the Frost & Sullivan 2018 Best Practices Awards

DENVER, May 23, 2018 /PRNewswire/ — NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), the nano-biotechnology company that has commercialized a patented delivery system known as the NanoSphere Delivery System™, has been awarded the 2018 Technology Innovation Award by Frost & Sullivan as part of the annual Best Practices Awards for North America. These awards recognize excellence across a number of fields and are the result of independent research conducted by Frost & Sullivan, which specializes in business growth partnerships.

NanoSphere Health Sciences

The Technology Innovation category of 2018 was awarded based on criteria including technology attributes, future business value, application diversity, customer acquisition and beyond. Previous winners of this Technology Innovation Award include key pharmaceutical players such as Nemaura Medical, Boehringer Ingelheim, 3M and Acino.

Independent research concluded that NanoSphere Health Sciences has achieved truly superior delivery of pharmaceutical, cosmetic, and nutraceutical agents and that it outperforms competing solutions by providing significant biocompatibility, safety, efficacy and versatility. It was recognized that NanoSphere Health Sciences has effectively solved a complex problem in drug delivery with its unique ability to control the efficacy of drug formulations once inside the body.

The NanoSphere Delivery System™ is a smart lipid nanoparticle delivery platform. Patented ‘NanoSpheres’, or lipid nanoparticles, nano-encapsulate biological agents into a protective, phospholipid membrane. The encapsulated ingredients are rapidly delivered through the skin or mucosa to targeted sites with increased bioavailability, bioactivity and therapeutic potential. NanoSphere Health Sciences recently received the patent for this technology, giving it ownership over the biggest development in non-invasive medical delivery in over 25 years.

NanoSphere Health Sciences has developed products that successfully leverage the next-generation NanoSphere Delivery System™ in the cannabis industry. The company’s revolutionary Transdermal NanoSerum™, a serum delivering cannabinoids through the skin, is ideal for localized pain and inflammation, as well as providing systemic therapy and relief from anxiety. The nano-encapsulation technology significantly increases the bioavailability of cannabis when compared to NanoSphere’s competitors. NanoSerum™ is already commercially available in Colorado under the company’s brand name Evolve Formulas and will soon launch in California, Arizona and Nevada.

“The recognition of our NanoSphere Delivery System™ as a breakthrough innovation is a direct reflection of our team’s dedication to finding inventive solutions for improving the effectiveness and precision of how medical benefits are delivered,” said Robert Sutton, CEO of Nanosphere Health Sciences and Evolve Formulas. “Receiving this prestigious honor represents the culmination of many years of careful research, development and formulation.”

“NanoSphere Health Sciences stood out from its competitors in the 2018 Technology Innovation category. Each year, we look for disruptive technology that solves the most complex problems in the scientific world,” said Marta Piotrowska, Senior Research Analyst at Frost & Sullivan, who provided the independent analysis that led to this award. “Looking ahead, the application potential for this revolutionary NanoSphere Delivery System™ is limitless, stretching from big pharma to the personal care and beauty markets. For its strong overall performance that addresses major challenges and opens opportunities within the nano-encapsulation market, NanoSphere Health is recognized with Frost & Sullivan’s 2018 Technology Innovation Award.”

For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 702-957-6203.

On behalf of the Board

Robert Sutton, Chairman and CEO

Office: 720-520-4282
Email: rsutton@nanospherehealth.com

Investor Contact:

Victor Goncalves, Executive Vice President

Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

For more information contact:
Emily Kielthy
emily@rosengrouppr.com
702-957-6203

 

NanoSphere Health Sciences is providing next-generation delivery of nutraceuticals & supplements, over-the-counter medications for the cannabis, pharmaceutical, and animal health products, and beyond. Cutting-edge NanoSphere Delivery Systems™ are up to 6 times more bioavailable and improve product quality. Patent-pending NanoSpheres provide superior delivery of a wide-range of bioactive compounds. NanoSphere Health Sciences helps people achieve better health more rapidly and effectively. (PRNewsfoto/NanoSphere Health Sciences, LLC)

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/nanosphere-health-sciences-wins-prestigious-frost–sullivan-2018-technology-innovation-award-300653368.html

SOURCE NanoSphere Health Sciences INC

 

Source: PR Newswire (May 23, 2018 – 8:30 AM EDT)

The post NanoSphere Health Sciences Wins Prestigious Frost & Sullivan 2018 Technology Innovation Award appeared first on CannabisFN.

Pivot Secures Manufacturing Facility in Costa Mesa, California

Written by Ryan Allway on

U.S. Subsidiary Pivot Naturals LLC To Submit Applications For Cannabis Business Licenses

VANCOUVER, May 23, 2018 /PRNewswire/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to announce that its wholly-owned U.S. subsidiary, Pivot Naturals LLC, (“PNL”), has executed a lease agreement for a manufacturing facility in Costa Mesa, California’s Measure “X” Zone. Pivot Naturals will immediately submit an application to obtain a Marijuana Business Permit, as well as a Conditional Use Permit and a Business License. Businesses in Costa Mesa’s Measure “X” Zone that meet the requirements for operation can conduct wholesale medical marijuana distributing, manufacturing, processing and transporting as well as establish research and development and testing laboratories.

Pivot intends to use this building to create a state-of-the-art GMP manufacturing facility to begin production of its suite of patented products to be marketed under the brand name ‘Pivot Naturals’. PNL will acquire high quality cannabis oil and isolates and use its patented method to convert oil-to-powder (“RTIC”- Ready To Infuse Cannabis) to launch finished products such as capsules, stick packs and bulk additives for sale and distribution in the California market. RTIC is a patented technology that enables the Company to cost-effectively turn cannabis oil into dry powder, which can subsequently be used in their health and wellness products, baking additives, pet products, and B2B beverage and edibles ingredients. A portion of the manufacturing facility has been earmarked to create production lines of topical creams and oral solutions utilizing the Company’s additional patented drug delivery technologies.

Mr. Patrick J. Rolfes, President of Pivot Naturals, LLC stated “We are excited to have secured our manufacturing facility, which will also serve as our U.S. Corporate offices, in Costa Mesa, California. We can now focus on bringing Pivot’s high-quality and technically advanced products to California consumers through our established relationships with state-wide licensed distributors.  I expect that we will receive the necessary local and state manufacturing licenses in July 2018 and complete production equipment installation by August 2018. Pivot Naturals’ capsules, stick packs and bulk powder should be on the shelves of dispensaries in California by Q4 2018. In addition, we have been inundated by requests to supply our patented RTIC powder for white label products and we fully intend to continue to sign manufacturing and supply agreements with respected cannabis brands in our state.”

California, the largest state economy in the US and the sixth largest economy in the world, is also the largest marijuana market on the planet with annual legal sales totaling approximately $2.8 billion in 2016. January 1, 2018 shepherded both California’s economy and its cannabis market into a new era of growth with the legalization of the world’s largest adult-use recreational market. A recent BDS Analytics report says California’s legal cannabis market could grow to $3.7 billion in 2018 and reach $5.1 billion to rival the beer market by 2019.

“Securing a manufacturing facility in California is a major milestone for Pivot, enabling the Company to generate revenue in 2018, in the largest cannabis market in the world,” said Dr. Patrick Frankham, CEO of Pivot Pharmaeuticals. “Mr. Rolfes and his team continue to successfully execute our U.S. business strategy.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Cision View original content:http://www.prnewswire.com/news-releases/pivot-secures-manufacturing-facility-in-costa-mesa-california-300653486.html

SOURCE Pivot Pharmaceuticals Inc.

 

Source: PR Newswire (May 23, 2018 – 8:00 AM EDT)

The post Pivot Secures Manufacturing Facility in Costa Mesa, California appeared first on CannabisFN.